

## CURRICULUM VITAE

**DATE UPDATED:** November, 2016

**NAME:** **CHRISTOPHER R. McCURDY, Ph.D., F.A.A.P.S.**

**DATE, PLACE OF BIRTH:** March 29, 1971; Pittsburgh, Pennsylvania

**ADDRESS:** Work: Interim Chair, Department of BioMolecular Sciences  
Professor of Medicinal Chemistry  
Professor of Pharmacology  
Research Professor, RIPS  
Director, NIH COBRE CORE-NPN  
School of Pharmacy  
University of Mississippi  
419 Faser Hall  
University, MS 38677-1848  
Phone: (662) 915-5882  
Fax: (662) 915-5638  
email: [cmccurdy@olemiss.edu](mailto:cmccurdy@olemiss.edu)

### **EDUCATION**

<u>Institution</u>	<u>Degree</u>	<u>Year</u>
The University of Georgia College of Pharmacy Department of Pharmaceutical and Biomedical Sciences (Former Department of Medicinal Chemistry) Athens, Georgia 30605 Dissertation Advisor: Dr. J. Warren Beach; Dissertation Title: "Cholinergic Channel Modulators: Analogs of Lobeline."	Ph.D. Medicinal Chemistry	1998
Ohio Northern University Raabe College of Pharmacy Ada, Ohio 45810	B.S. Pharmacy	1994

### **POSTDOCTORAL FELLOWSHIP**

<u>Institution</u>	<u>Position</u>	<u>Dates</u>
University of Minnesota College of Pharmacy Department of Medicinal Chemistry Minneapolis, MN 55455 Advisor: Distinguished Professor Philip S. Portoghese	NIDA/NIH Research Training Award	1998 – 2001

### **LICENSURE**

United States Department of Justice, Drug Enforcement Administration Research License, 2003  
– Present

Registered Pharmacist: State of Minnesota, License #116692-7. 1998 – 2002

Registered Pharmacist: State of Georgia, License #18003. 1994 – 2010

**ACADEMIC APPOINTMENTS**

07/16 – present	Interim Chair, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS
01/14 – present	Professor of Medicinal Chemistry, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS
01/14 – present	Professor of Pharmacology, Department of BioMolecular, School of Pharmacy, University of Mississippi, University, MS
07/13 – 01/14	Professor of Medicinal Chemistry, Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS
07/13 – 01/14	Professor of Pharmacology, Department of Pharmacology, School of Pharmacy, University of Mississippi, University, MS
07/08 – 06/11	Dean's Advisory Committee Distinguished Teaching Scholar, School of Pharmacy, University of Mississippi, University, MS (Three-year appointment, second continuous cycle - only 2 cycles allowed)
07/07 – 06/13	Associate Professor of Medicinal Chemistry, Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS
07/07 – 06/13	Associate Professor of Pharmacology, Department of Pharmacology, School of Pharmacy, University of Mississippi, University, MS
07/05 – 06/08	Dean's Advisory Committee Distinguished Teaching Scholar, School of Pharmacy, University of Mississippi, University, MS (Three-year appointment)
09/04 – 06/07	Assistant Professor of Pharmacology, Department of Pharmacology, School of Pharmacy, University of Mississippi, University, MS
07/01 – 06/07	Assistant Professor of Medicinal Chemistry, Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS
08/94 – 05/98	Graduate Teaching Assistant, Department of Medicinal Chemistry, College of Pharmacy, University of Georgia, Athens, GA

**SCIENTIFIC APPOINTMENTS/EXPERIENCE**

11/16 –	President-Elect, American Association of Pharmaceutical Scientists (AAPS), Alexandria, VA
07/16 – Present	Director, NIH-COBRE Center of Research Excellence in Natural Products Neuroscience (CORE-NPN), University of Mississippi
04/16 – 07/16	Research Development Faculty Fellow, Office of Research and Sponsored Programs, University of Mississippi, University MS
09/15 – Present	Board of Grants, American Foundation for Pharmaceutical Education, Alexandria, VA
09/15 – Present	Review Editor, Editorial Board of Frontiers in Neuropharmacology, a specialty of Frontiers in Neurology, Neuroscience, Pharmacology and Psychiatry, <a href="http://www.frontiersin.org">www.frontiersin.org</a>
02/15 – Present	Member, United States Pharmacopeial Convention, AAPS voting member
03/14 – Present	Research Team Member, Research Center on Substance Abuse and Depression, Roseman University of Health Sciences, Henderson, NV
11/13 – Present	Executive Council (Board of Directors) Member-At-Large, American Association of Pharmaceutical Scientists, Alexandria, VA

07/13 – Present Research Professor, Research Institute for Pharmaceutical Sciences, University of Mississippi, University, MS

06/12 – 10/12 Editor-In-Chief, Ad Hoc, AAPS PharmSciTech, AAPS Publications

03/12 – Present Editorial Board of Referees, Arkivoc Journal, ARKAT USA, Inc.

01/12 – 08/15 Editorial Advisory Board Member, Letters in Drug Design and Discovery, Bentham Publishing

01/12 – Present Editorial Board, Scientifica - Pharmaceuticals, online open access

02/11 – 07/11 Associate Editor, Ad Hoc, AAPS PharmSciTech, AAPS Publications

01/11 – Present Editorial Advisory Board Member of the Journal of Medicinal Chemistry, American Chemical Society Publications

01/11 – Present Senior Editor, Medicinal Chemistry Research, Springer

01/11 – Present Editorial Board Member of the World Journal of Pharmacology, Baishideng Publishing Group Co., Limited

09/10 – 06/16 Co-Director, NIH-COBRE Center of Research Excellence in Natural Products Neuroscience (CORE-NPN), University of Mississippi

07/08 – Present Editorial Board Member of Future Medicinal Chemistry, Future Science Group

04/08 – Present Editorial Board Member of Current Bioactive Compounds, Bentham Publishing

02/08 – Present Editorial Board Member of The Open Enzyme Inhibition Journal, Bentham Publishing

07/07 – 06/13 Research Associate Professor, Research Institute for Pharmaceutical Sciences, University of Mississippi, University, MS.

01/07 – Present Editorial Board Member of Open Medicinal Chemistry, Bentham Publishing

01/07 – Present Editorial Board Member of Perspectives in Medicinal Chemistry, Libertas Academica

04/06 – 09/09 Editorial Advisory Board Member of Current Topics in Medicinal Chemistry, Bentham Publishing

02/06 – Present Editorial Board Member of Pharmacologyonline

07/05 – Present Senior Editorial Board of Molecular Conceptor Medicinal Chemistry Curriculum, Synergix Ltd.

01/02 – 12/11 New Trends Editor, Medicinal Chemistry Research, Springer Boston.

07/01 – 06/07 Research Assistant Professor, Research Institute for Pharmaceutical Sciences, University of Mississippi, University, MS.

07/98 – 07/01 Post-Doctoral Fellow. Research Training Award Fellow, National Institute on Drug Abuse, University of Minnesota, College of Pharmacy, Department of Medicinal Chemistry, Minneapolis, MN. Advisor: Distinguished Professor Philip S. Portoghese.

08/96 – 06/98 Coordinator of Bruker NMR Facility, University of Georgia, College of Pharmacy, Athens, GA.

06/93 – 08/93 Undergraduate Research Fellow, Department of Medicinal Chemistry, College of Pharmacy, University of Georgia, Athens, GA. Advisor: Professor C. DeWitt Blanton.

09/93 – 12/93 Research Assistant, Department of Pharmaceutical and Biomedical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, OH. Advisor: Assistant Professor David Kinder.

09/91 – 05/92            Research Assistant, Department of Pharmaceutical and Biomedical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, OH. Advisor: Assistant Professor Stephen J. Cutler.

### **PROFESSIONAL PHARMACY APPOINTMENTS/EXPERIENCE**

09/98 – 07/01            Pharmacist, Part-time, SuperValu Pharmacy, Minneapolis, MN  
07/94 – 07/98            Pharmacist, Part-time, Publix Super Markets, Inc., Atlanta, GA  
05/94 – 07/94            Graduate Pharmacy Intern, Phar-Mor, Inc., Youngstown, OH  
03/87 – 05/94            Pharmacy Technician, Phar-Mor, Inc., Youngstown, OH

### **STUDENT AND TECHNICIAN SUPERVISION, PRECEPTING AND ADVISING**

#### **Dissertation/Thesis Committee Director**

##### Doctor of Philosophy

University of Mississippi, Department of Medicinal Chemistry, University, Mississippi

- Ashok E. Philip, 10/01 – 08/06 (Ph.D. defense August 22, 2006)
- Nidhi Singh, 12/02 – 5/07 (Ph.D. defense May 4, 2007)
- Neha Vyas Philip, 12/02 – 04/07 (Ph.D. defense April 20, 2007)
- Jessica Erin Adkins, 5/04 – 10/08 (Ph.D. defense October 8, 2008)
- Sanju Narayanan, 12/04 – 2/09 (Ph.D. defense February 27, 2009)
- Tammy Nolan, 12/04 – 01/10 (Ph.D. defense January 22, 2010)
- Velvet Blair Journigan, 9/05 – 04/10 (Ph.D. defense April 28, 2010)
- Marco Arribas, 12/04 – 11/10 (Ph.D. defense November 3, 2010)
- Edward “Sonny” B. Furr, 10/06 – present
- Rohit Bhat, 10/06 – 11/11 (Ph.D. defense November 8, 2011)
- David Watson, 12/07 – 11/13 (Ph.D. defense November 19, 2013)
- Jessica Mankus, 12/07 – 11/12 (Ph.D. defense July 23, 2012)
- Walid Alsharif, 03/10 – 12/15 (Ph.D. defense December 2, 2015)
- Kelsey Gabrielle Luecke McPherson, 8/13 – present
- Lisa Leona Wilson, 1/14 – present
- Kareem Galal, 1/15 – present
- John Fortner, 8/15 – present
- Heba Agha, 8/15 – present
- Vedanjali Gogineni, 7/16 – present
- Morgan Crowley, 8/16 – present

Beni-Suef University, Beni Suef, EGYPT

- Ahmed Hassan Abdelazeem, 8/08 – 10/10 (Ph.D. defense in Egypt January 12, 2011)

##### Master of Science

University of Mississippi, Department of Medicinal Chemistry, University, Mississippi

- Shivangi Awasthi, 8/11 – 11/13 (M.S. defense November 21, 2013)

### Senior Thesis

University of Mississippi, Sally McDonnell Barksdale Honors College, University, Mississippi

- Joshua Swan Taylor, 12/06 – 4/07 (Thesis defense April 16, 2007)
- Ashley Jasmine Stubblefield, 7/06 – 4/07 (Thesis defense April 26, 2007)
- Andrea Malone Green, 12/06 – 4/08 (Thesis defense April 9, 2008)
- Sarah E. Clark, 12/07 – 04/09 (Thesis defense April 15, 2009)
- Yang Song, 09/09 – 08/10 (left to attend pharmacy school at the University of MN)
- Jonathan Shih, 01/10 – 05/13 (Thesis defense May 3, 2013)
- Jessie J. Xie, 06/10 – 04/13 (Thesis defense April 30, 2013)
- Chad Burch, 09/12 – 05/16 (decided to drop Honors College)
- John Yi, 03/13 – 05/16 (Thesis defense April 29, 2016)
- May Ly, 05/13 – 04/15 (Thesis defense April 16, 2015)
- Jason Teng, 12/13 – 04/15 (Thesis defense April 30, 2015)
- Jennifer Miller, 03/14 – 05/16 (Thesis defense March 28, 2016)
- Jacqueline Morris, 06/14 – present
- Jamie Stone, 7/15 – present

### Advisory Committee Member

#### Doctor of Philosophy

University of Mississippi, Department of BioMolecular Sciences, University, Mississippi  
(department formed in 2014 by combination of Medicinal Chemistry, Pharmacology and Pharmacognosy)

#### Division of Medicinal Chemistry

- Pankaj Pandey, 11/14 – 11/15 (Defense November 30, 2015)
- Amer Tarawneh, 11/14 – 11/15 (Defense November 16, 2015)
- Vedanjali Gogineni, 4/15 – present

#### Division of Pharmacology

- Rhianna Morgan, 7/15 – present
- Taisen Hao, 5/16 – present

University of Mississippi, Department of Medicinal Chemistry, University, Mississippi

- Aaron Beeler, 09/01 – 05/02
- Yogesh Sabnis, 06/02 – 12/02
- Maralea Gourley, 11/03 – 01/04
- Lindsay Odom, 04/04 – 06/06
- S. Anand, 10/04 – 05/08
- Li Zi, 12/04 – 01/06
- Cassia S. Mizuno, 09/05 – 05/06
- Nakul Telang, 10/05 – 12/07
- Young Kim, 10/06 – 11/08
- Seoung-Ryoung Choi, 3/06 – 12/06
- Akshay Patney, 10/06 – 8/07
- Prasenjit Mukherjee, 9/07 – 6/08

- David Weldon, 09/07 – 8/08
- Tuwanda Simmons, 07/08 – 09/09
- Sarah Chajkowski Scarry, 07/10 – 04/12
- Afeef Husni, 11/11 – 07/12
- Xiaoning Wang, 11/11 – 07/12

University of Mississippi, Department of Pharmacognosy, University, Mississippi

- Jeremy Stewart, 07/02 – 02/05

University of Mississippi, Department of Pharmaceutics, University, Mississippi

- Praveen K. Mididoddi, 5/05 – 04/06
- Harsha Vinnakota, 9/09 – 11/10
- Pradeep Kumar Vuppala, 09/09 – 04/12
- Seshulatha Jamalapuram, 09/09 – 11/12
- Sai Prasad Boddu, 09/09 – 11/10

University of Mississippi, Department of Chemistry and Biochemistry, University, Mississippi

- Brian W. Hopkins, 01/03 – 04/06
- Emily Rowland, 12/04 – 05/05
- Lingzhi Sun, 04/08 – 05/10
- Rajesh Kota, 11/08 – 01/12

University of Mississippi, Department of Psychology, University, Mississippi

- Jason E. Warnick, 8/03 – 05/07
- Matthew Feltenstein, 12/03 – 08/04

#### Master of Science

University of Mississippi, Department of Medicinal Chemistry, University, Mississippi

- Tiffany D. Clark, 4/08 – 6/08
- Zarana Chauhan, 4/13 – 7/13

University of Mississippi, Department of Pharmacology, University, Mississippi

- Nidhi Kaushal, 11/07 – 03/08
- James Fishback, 11/07 – 8/08

#### Sally McDonnell Barksdale Honor's College Senior Thesis

- Morgan Davis, 10/14 – 12/14
- Lindsay Wencel, 12/14 – 04/15
- John Fitzpatrick, 12/14 – 04/15
- John Franklin, 12/14 – 04/15
- Kelsey Pettus, 2/16 – 5/16
- Ashley Noblin, 1/16 – 4/16

**Research Supervisor**

University of Mississippi, School of Pharmacy, University, Mississippi.

Research Scientist

- Dr. Christophe Mesangeau, 9/07 – 07/12
- Dr. Juan Francisco Leon, 7/16 – present

Postdoctoral Fellow

- Dr. Surya Vangapandu, 9/02 – 11/04
- Dr. Marcelo J. Nieto, 10/02 – 9/06
- Dr. Gweneal Cheve, 02/04 – 05/06
- Dr. Christophe Mesangeau, 10/04 – 08/07
- Dr. Jianmei Cui, 11/06 – 2/09
- Dr. Basile Peres, 9/07 – 1/09
- Dr. Anthony Comeau, 06/13 – 10/13
- Dr. Coco Nankwa Kapanda, 2/14 – 12/15
- Dr. Marco Mottinelli, 2/15 – present
- Dr. Sebastiano Intagliata, 5/16 – present

Research & Development Biologist

- Ms. Lisa Leona Wilson, 01/13 – present

Ph.D. Candidate

- Ashok E. Philip, 10/01 – 08/06
- Nidhi Singh, 12/02 – 05/07
- Neha Vyas, 12/02 – 04/07
- Mark Jaggars, 12/02 – 06/03 (left program)
- Jessica E. Adkins, 05/04 – 10/08
- Marco Arribas, 12/04 – 11/10
- Tammy L. Nolan, 12/04 – 01/10
- Sanju Narayanan, 12/04 – 2/09
- Velvet B. Journigan, 10/05 – 04/10
- Edward B. Furr, 10/06 – 07/13 (left program)
- Rohit Bhat, 10/06 – 11/11
- David E. Watson, 12/07 – 11/13
- Jessica V. Mankus, 12/07 – 11/12
- Walid Alsharif, 03/10 – 12/15
- Kelsey G. Luecke McPherson, 08/13 – present (admitted to candidacy)
- Lisa L. Wilson, 01/14 – present
- Kareem Galal, 01/15 – present
- John Fortner, 8/15 – present
- Heba Agha, 8/15 – present
- Morgan Crowley, 8/16 – present

M.S. Candidate

-Shivangi Awasthi, 8/11 – 11/13

Visiting Graduate students (Ph.D. Candidates)

-Nicola Fazio, 7/07 – 04/08 (University of Bologna, Bologna, Italy)  
-Ahmed Hassan Abdelazeem, 8/08 – 10/10 (Beni-Sueif University, Egypt)  
-Natalia Valadares de Moraes, 8/08 – 12/08 (University of Sao Paulo, Brazil)  
-Emanuele Amata, 01/09 – 5/09 (University of Catania, Italy)  
-Sebastiano Intagliata, 7/15 – 9/15 (University of Catania, Italy)

Undergraduate students

-Bryan Miller, 06/03  
-Azadeh Mirbagheri, (Belgium) 07/03  
-Alexia Jadot, (Belgium) 07/03  
-Stephen S. Scully, 05/04 – 07/05  
-Julie Reuther, 09/04 – 12/04  
-Jameika Stuckey, 04/05 – 05/06  
-Adel Elsohly, 05/05 – 08/07  
-Grant Smith, 05/05 – 05/06  
-Leigh Ann Tadlock, 09/05 – 05/06  
-Jennnifer Nobles, 09/05 – 05/06  
-Rachel Camburn, 01/06 – 05/06  
-Ashley Stubblefield, 07/06 – 05/07  
-Neil White, (Princeton University) 06/06 – 08/06, 07/07 – 08/07  
-Jean Francois Deneff, (Belgium) 07/06 – 08/06  
-Joffory Mulongo, (Belgium) 07/06 – 08/06  
-Bilal Souilem, (Belgium) 07/06 – 08/06  
-Natalia Valadares de Moraes, (Brazil) 08/06 – 11/06  
-Andrew Whitaker, 9/06 – 05/07  
-Andrea Malone Green, 12/06 – 5/08  
-Ronald Kim, 7/07 – 9/07  
-Nihed Draoui, (Belgium) 7/07 – 08/07  
-Olayinka Fasanya, (Belgium) 7/07 – 08/07  
-Sabrina Montante, (Belgium) 7/07 – 08/07  
-Sarah E. Clark, 12/07 – 5/09  
-Jessica Hall, 6/08 – 7/08  
-Florian Langer, (Belgium) 7/08  
-Yang Song, 7/09 – 8/10  
-Jonathan Shih, 2/11 – 5/13  
-Jessie J. Xie, 06/10 – 5/13  
-Florian Thinard, (Belgium) 07/12  
-Chad Burch, 09/12 – 05/16  
-John Yi, 03/13 – 08/16  
-May Ly, 03/13 – 04/15  
-Neal Tisher, 06/13 – 07/13



- Jason Teng, 01/14 – 04/15
- Jennifer Miller, 03/14 – 04/16
- Jacqueline Morris, 06/14 – present
- Ethan Collier, 06/14 – 07/14
- Mary “Caroline” Morris, 06/14 – 07/14
- Morgan Crowley, 6/15 – 7/15
- Jamie Stone, 6/15 – present
- Garrett Rogers, 6/16 – present
- Jonah Harrington, 8/16 – present

#### High School students

- Neil White, 06/04 – 07/04 (Oxford High School, Oxford, MS)
- Andrew Mullen, 06/10 – 07/11 (Oxford High School, Oxford, MS)
- Taide Ding, 07/10 – 08/13 (Oxford High School, Oxford, MS)

University of Minnesota, Department of Medicinal Chemistry, Minneapolis, MN.  
M.S. Candidate

- Amol Kulkarni, 09/99 – 07/01

University of Georgia, Department of Medicinal Chemistry, Athens, GA.  
Summer Undergraduate Intern

- Reagan Miller, 06/97 – 08/97

#### **University of Mississippi School of Pharmacy Professional Development Advising Team**

- 08/14 – present Philip Kelly, Rachel Lee, May Ly, Jim Still, Jessica Thornsburg, Lily Van, Payton Brown, Lauryn Easterling, MacKenzie Lewis
- 08/13 – present Emily Buckley, Jordan Michaels, Colleen Riley, Jessica Ruiz, Andrew Smelser, Stephanie Sollis, Blake Williams

#### **Pharmacy Undergraduate Student Faculty Mentor**

Fall 2006 formal mentoring program ended by School of Pharmacy.

- 08/05 – 08/06 Stephanie Davis, Samuel King, Wesley Pierce, Janelle Austrom, Lauren Courtney, Jay Gulley, Bailey Melton, Sally Putt, Andrea Rowling, Bart Smith, Makena Swanson, Jennifer Chadwick, Erin Clark, Lara Garrard, Holly Massey, Haley Peel, May Shackelford, Laura Summerford
- 08/04 – 05/05 Sally Putt, Andrea Rowling, Laura Carpenter, Holly Massey, May Shackelford, Lara Youngblood, Stephen Scully.
- 08/03 – 05/05 Sheila Gilliland, Jennifer Hutchinson, Kimberly Mann Dorrah, Patrick Obriant, Ryan Sewell, Melissa Williams Greene, Matt Windham, Haley Peel.
- 08/02 – 05/04 Ann Magee, Amanda Massengill, Carolyn McClure, Megan McGinnis, Marin Myers, Brandi Wise.
- 08/02 – 05/03 Suvapun Bunniran, Jennifer Cameron, Troy Hudson, Debralee Jefcoat, Tywanda Jefferson, Haley Phelps, Stephen Poole.

## SCIENTIFIC/PROFESSIONAL ASSOCIATIONS

### Scientific Associations

American Chemical Society, Member, 1994 – present  
Medicinal Chemistry Division Member, 1994 – present  
Ole Miss Local Section Member, 2001 – present  
Secretary 2004 – 2005  
Journal of Medicinal Chemistry, Editorial Advisory Board Member, 2011 – present  
3rd Portuguese Lectureship Selection Committee, 2011 – 2012 (JMC EAB representative)  
5th Portuguese Lectureship Selection Committee, 2013 – 2014 (JMC EAB representative)  
6<sup>th</sup> Portuguese Lectureship Selection Committee, 2015 (JMC EAB representative)  
American Association for the Advancement of Science, Member, 2001 – present  
American Association of Pharmaceutical Scientists, Member, 1996 – present  
National Biotechnology Conference Planning Committee, 2003 – 2004  
Vice-Chair, Drug Design and Discovery (DDD) Section, 2005 – 2006  
Chair-Elect, Drug Design and Discovery (DDD) Section, 2006 – 2007  
Chair Drug, Design and Discovery (DDD) Section, 2007 – 2009  
Past-Chair, Drug Design and Discovery (DDD) Section, 2009 – 2010  
Chair-Elect, AAPS Publications Committee, 2010 – 2011  
Chair, AAPS Publications Committee, 2011 – 2012  
Past-Chair, AAPS Publications Committee, 2012 – 2013  
Co-Chair, 2012 AAPS Annual Meeting Planning Committee, 2011 – 2012  
Chair, 2013 AAPS Annual Meeting Planning Committee, 2012 – 2013  
Past-Chair, 2014 AAPS Annual Meeting Planning Committee, 2013 – 2014  
Member-At-Large, Executive Council, AAPS, 2013 – 2016  
Fellow, 2014  
Voting Delegate to the United States Pharmacopeial Convention, 2015 – present  
President-Elect, Executive Council, AAPS, 2016 – present  
International Narcotics Research, Member, 2002 – present  
Organizing Committee Member, 2012 meeting, Kansas City, MO  
Sigma Xi, The Scientific Research Society, Member, 1997 – present  
Ole Miss Local Section  
President-Elect, 2006 – 2008  
President, 2008 – 2010  
Society for Neuroscience, Member, 2003 – present  
American Society of Pharmacognosy, Member, 2007 – present  
United States Pharmacopeial Convention, Member, 2015 – present  
International Pharmaceutical Federation (FIP), 2015 – present  
Co-Chair, Drug Design and Discovery Special Interest Group, 2015 – present  
International Cannabinoid Research Society, Member, 2016 – present

## **Professional Associations**

### National

American Association of Colleges of Pharmacy, Member 1998 – present  
-Academic Leadership Fellow, 2005 – 2006  
-Council of Faculties Nominations Committee, 2012  
American Pharmaceutical Association, Member. 1994 – 1995  
Phi Delta Chi Pharmaceutical Fraternity, Member, 1989 – present  
-National Executive Committee Member, 1992 – 1993  
-Mid-West Regional Correspondent, 1992 – 1993

### State

Mississippi Pharmacists Association, 2007 – present  
Minnesota Pharmacists Association, 1998 – 2000  
Georgia Pharmacy Association, 1994 – 1998  
Ohio Pharmacists Association, 1991 – 1994

### Local

Phi Delta Chi Pharmaceutical Fraternity, Alpha Upsilon Chapter, Ohio Northern University, Ada, OH  
-Chapter President, 1991 – 1992  
-Chapter Correspondent, 1990 – 1991

## AWARDS AND HONORS

Member, American Foundation for Pharmaceutical Education, Board of Grants, 2015 – present  
Speaker, TEDxUM (one of ten faculty selected from the University) – October 2015  
Inaugural recipient of AAPS Drug Discovery and Development Interface (DDDI) Section Service Award, 2015  
Member, United States Pharmacopeial Convention, AAPS Voting Delegate, 2015 – present  
Fellow, American Association of Pharmaceutical Scientists (AAPS), 2014  
Elected Member-At-Large, American Association of Pharmaceutical Scientists, 2013 – 2016  
The University of Mississippi Faculty Achievement Award, 2010  
Teacher of the Year, PY2 Class, School of Pharmacy, University of Mississippi, 2010  
Faculty Service Award, School of Pharmacy, University of Mississippi, 2009  
Dean's Advisory Committee Distinguished Teaching Scholar, School of Pharmacy, University of Mississippi, July 1, 2008 – June 30, 2011  
Faculty Research Award, School of Pharmacy, University of Mississippi, 2007  
Phi Kappa Phi, 2007  
Teacher of the Year by the third year pharmacy class, University of Mississippi, 2006  
Elected Vice-Chair of Drug Design and Discovery (DDD) section for the American Association of Pharmaceutical Scientists (AAPS), August 2005 – August 2011  
Inaugural Dean's Advisory Committee Distinguished Teaching Scholar, School of Pharmacy, University of Mississippi, July 1, 2005 – June 30, 2008  
American Association of Colleges of Pharmacy Academic Leadership Fellow, 2005 – 2006  
Distinguished Alumnus of the Year, Phi Delta Chi, Alpha Upsilon Chapter, Ohio Northern University, Ada, OH, 2005  
Teacher of the Year by third year pharmacy class, University of Mississippi, 2003  
Recipient of AACP New Investigator Award, 2002  
Recipient of Glaxo/Albert B. Prescott Leadership Award, 2002  
Recipient of Training Fellow Award, National Institute on Drug Abuse, University of Minnesota, Minneapolis, Minnesota, 1998-2001  
Recipient of University of Georgia, Medicinal Chemistry, Pre-Doctoral Fellowship, 1994-1998  
Sigma Xi Research Society, 1998  
Rho Chi Society (Pharmacy honor society), 1997  
Recipient of Allen and Hanburys/Glaxo Pride in Pharmacy Award, 1994  
Phi Lambda Sigma (Pharmacy leadership honor society), 1992  
Mortar Board, 1992  
Omicron Delta Kappa, 1992  
Phi Delta Chi Outstanding Member of the Year Award, 1992  
Recipient of Ohio Northern University Dean's Award, academic scholarship, 1989-1993

## **SERVICE AS SCIENTIFIC REFEREE**

### **Invited National Institutes of Health Referee (Ad-Hoc)**

1. National Institute on Drug Abuse – Contract Review on Non-clinical ADME Studies (N01DA-16-8931), July 13, 2016.
2. National Institute of Allergy and Infectious Disease – Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens R21/R33 2016/10 ZAI1 LR-M (S1) 1, May 10-12, 2016.
3. National Institute on Drug Abuse – Special Emphasis Panel 2016/08 ZDA1 LXF-L (31) S, March 15, 2016.
4. National Center for Complementary and Integrative Health – Clinical Research on Natural Products (R21 and R33) Special Emphasis Panel 2016/01 ZAT1 SM (38) S, November 4, 2015.
5. National Institute on Drug Abuse – Special Emphasis Panel 2015/08 ZDA1 LXF-L (31) S, April 5, 2015.
6. National Institute on Drug Abuse – Cutting-Edge Basic Research Awards (CEBRA) Program 2015/05 ZDA1 JXR-G (10) S, April 2, 2015.
7. National Institute of Allergy and Infectious Disease – Development of Novel Therapeutics for Select Pathogens (R21/R33), Gram-Negative Therapeutics (ZAI1-LR-M-M1), March 11-13, 2015.
8. National Institute of Allergy and Infectious Disease – Development of Novel Therapeutics for Select Pathogens (R21/R33), Influenza Therapeutics (ZAI1-LR-M-M2), March 9-10, 2015.
9. National Center for Complementary and Alternative Medicine – Special Emphasis Panel U41 Centers for Advancing Natural Products Innovation and Technology Centers (CANPIT), ZAT1 SM (35), December 19, 2014.
10. National Center for Complementary and Alternative Medicine – Special Emphasis Panel P50 Botanical Dietary Supplement Research Centers (BDSRC), ZAT1 SM (34) P, December 17-18, 2014.
11. National Institute on Drug Abuse – Special Emphasis Panel Contract Review on GMP Synthesis of Bulk Drug Substances (N01DA-15-8915), August 28, 2014.
12. National Institute on Drug Abuse – Special Emphasis Panel 2014/08 ZDA1 LXF-L (36) 1, March 30, 2014.
13. National Institute on Drug Abuse – Cutting-Edge Basic Research Awards (CEBRA) Program 2014/05 ZDA1 GXM-A (09) S, March 19, 2014.
14. National Institute on Drug Abuse – Contract Review on Non-clinical ADME Studies (N01DA-14-8916), March 11, 2014.
15. National Institute of Allergy and Infectious Disease – Center of Excellence for Translational Research (Teleconference) 2014/01 ZAI1 LR-M (J1) 1, September 17-19, 2013.
16. National Center for Advancing Translational Sciences (NCATS) – NCATS Preclinical Drug Development Review Group 2013/05 ZTR1 DPI-8 (01) TRND - 4. March 20-21, 2013.
17. National Institute on Drug Abuse – Special Emphasis Panel 2013/08 ZDA1 LXF-L (01) 1, March 18, 2013.
18. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 LXF-L (01) 1, March 5, 2012.

19. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 JXR-D (09) 1. RFA 12-005 Medications Development Program Projects for Substance-Related Disorders (P01), October 18-19, 2011.
20. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 JXR-D (06). RFA 12-001 New Molecular Entities to Treat Substance Use Disorders, May 24, 2011.
21. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 LXF-L (01), March 22, 2011.
22. National Institute of Mental Health – National Cooperative Drug Discovery sand Development Groups (NCDDDG) Special Emphasis Panel ZMH1 ERB-C (04), March 10, 2011.
23. National Institutes of Health Center for Scientific Review – Drug Discovery Special Emphasis Panel/Scientific Review Group 2011/01 ZRG1 MDCN-B (91) S, November 9-10, 2010.
24. National Institute of Diabetes and Digestive and Kidney Diseases – Cystic Fibrosis Research and Translational Core Centers ZDK1 GRB-W (M2). April 7-8, 2010.
25. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 LXF-L (01), March 21, 2010.
26. National Institute on Drug Abuse – Member Conflict: Drug Discovery Panel ZRG1 MDCN-B (02), March 9-10, 2010.
27. National Institute of Mental Health – National Cooperative Drug Discovery sand Development Groups (NCDDDG) Special Emphasis Panel ZMH1 ERB-C (03), March 1, 2010.
28. National Institute of Allergy and Infectious Disease – Special Emphasis Panel ZAI1 LR-M (M1) – Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (R01 and R43/44), January 26-27, 2010.
29. National Institute on Drug Abuse – SBIR contract review Panel RFC No. N43DA-10-7774 – Rapid and sensitive method for the determination of Nicotine and its metabolites in biological fluids, January 12-14, 2010.
30. National Institute on Drug Abuse – SBIR contract review panel RFC No. N43DA-10-2218 – New Technologies: Integrating Data From Prescription Monitoring Program(s) to Current Clinical Practice, December 16, 2009.
31. National Institutes of Health Center for Scientific Review – Drug Discovery for Neurodegenerative Diseases Special Emphasis Panel ZRG1 MDCN-B (91) S, November 3-4, 2009.
32. National Institutes of Health Chemical and Bioanalytical Sciences Fellowship Study Section (F04A), June 18-19, 2009.
33. National Institute on Drug Abuse – Contract Review on GMP Synthesis of Bulk Drug Substances (N01DA-9-8881), May 13, 2009.
34. National Institute on Drug Abuse – Special Emphasis Panel ZDA1 LXF-L (01), March 30, 2009.
35. National Institutes of Health Center for Scientific Review – Drug Discovery for Neurodegenerative Diseases Special Emphasis Panel ZRG1 MDCN-B (91), February 19-20, 2009.
36. National Institute on Drug Abuse – Contract Review on Non-clinical ADME Studies (N01DA-9-8883), December 11, 2008.
37. National Institute on Drug Abuse – Contract Review on the quantification of drugs of abuse and related substances in biological specimens (N01DA-9-7767), August 6, 2008.

38. National Institutes of Health Chemical and Bioanalytical Sciences Fellowship Study Section (F04A) ZRG1 F04A-T (20)L, June 26, 2008.
39. National Institute for Research Resources – Science Education Partnership Award (SEPA) Special Emphasis Panel ZRR1 SEPA-9 01, March 2007.
40. National Institute for Research Resources – Science Education Partnership Award (SEPA) Special Emphasis Panel ZRR1 SEPA-9 01, March 2006.
41. National Institute of Allergy and Infectious Disease – Special Emphasis Panel ZAI-1-LR-M-M1, January/February 2006.
42. National Institute of Diabetes and Digestive and Kidney Diseases – Special Emphasis Panel ZDK1 GRB-6 (M1), April 19, 2005.
43. National Institute of Allergy and Infectious Disease-sponsored RFA, 2004.

#### **Invited Austrian Science Fund (FWF) Referee**

Translational Research Programme (TRP) – November 27, 2009 (contact Silvia Spitzer [Silvia.Spitzer@fwf.ac.at](mailto:Silvia.Spitzer@fwf.ac.at))

#### **Invited Neurological Foundation of New Zealand Referee**

Neurological Foundation Peer Review – October 25, 2012 (contact Douglas Ormrod [douglas.ormrod@neurological.org.nz](mailto:douglas.ormrod@neurological.org.nz))

Neurological Foundation Peer Review – May 17, 2012 (contact Douglas Ormrod [douglas.ormrod@neurological.org.nz](mailto:douglas.ormrod@neurological.org.nz))

#### **Invited National Research Foundation of South Africa**

Research and Innovation Support and Advancement Peer Review – October 3, 2012 (contact Nosisa Dube [nosisa.dube@nrf.ac.za](mailto:nosisa.dube@nrf.ac.za))

#### **Invited Journal Referee**

Medicinal Chemistry Research 1998 – present  
Expert Opinion on Therapeutic Patents, 1998  
Journal of Medicinal Chemistry 1999 – present  
Biopolymers (Peptide Science), 2003 – present  
Current Medicinal Chemistry, 2003 – present  
Journal of Natural Products, 2003 – present  
Bioorganic & Medicinal Chemistry Letters, 2004 – present  
Molecules, 2004 – present  
Neurochemical Research, 2004 – present  
Journal of Pharmacy & Pharmaceutical Sciences, 2004 – present  
Current Topics in Medicinal Chemistry, 2004 – present  
Synapse, 2005 – present  
Life Sciences, 2005 – present  
Peptides, 2005 – present  
Organic Letters, 2005 – present  
Journal of Combinatorial Chemistry, 2005 – present  
Proceedings of the National Academy of Science, USA, 2005 – present

Letters in Organic Chemistry, 2006  
Chimica Oggi (Chemistry Today), 2006  
Journal of Pharmacy and Pharmacology, 2006  
Combinatorial Chemistry and High Throughput Screening, 2006  
American Journal of Pharmaceutical Education, 2006 – present  
Tetrahedron, 2007 – present  
Archiv der Pharmazie, 2007 – present  
Chemical Reviews, 2007 – present  
Tetrahedron Letters, 2007 – present  
Journal of Pharmacology and Experimental Therapeutics, 2007 – present  
The Open Medicinal Chemistry Journal, 2008 – present  
Current Bioactive Compounds, 2008 – present  
Pharmacology, Biochemistry and Behavior, 2008 – present  
Journal of Computer Information and Modeling, 2008 – present  
British Journal of Pharmacology, 2008 – present  
Bioorganic Medicinal Chemistry, 2008 – present  
Molecular Pharmaceutics, 2008 – present  
Journal of the American Chemical Society, 2008 – present  
Neuropsychopharmacology, 2008 – present  
Synthesis, 2008 – present  
Future Medicinal Chemistry, 2009 – present  
Protein and Peptide Letters, 2009 – present  
Journal of Computer-Aided Molecular Design, 2009 – present  
Journal of Molecular Graphics and Modeling, 2009 – present  
BMC Research Notes, 2009 – present  
Neuroscience Letters, 2009 – present  
ACS Chemical Neuroscience, 2009 – present  
Journal of Structural Biology, 2009 – 2010  
ACS Medicinal Chemistry Letters, 2010 – present  
Current Pharmaceutical Design, 2010 – present  
ACS Combinatorial Science, 2010 – present  
The Journal of Physical Chemistry, 2011 – present  
Journal of Antibiotics, 2011  
European Journal of Medicinal Chemistry, 2011 – present  
E-Journal of Chemistry, 2012  
Neuroscience & Biobehavioral Reviews, 2012  
PLOS ONE, 2012  
Journal of Pharmaceutical Sciences, 2014  
Forensic Science International, 2014  
Zeitschrift für Naturforschung C, 2014  
ChemMedChem, 2015

### **Editorial Appointments**

New Trends Editor, Medicinal Chemistry Research, Springer, 2002 – 2010  
Senior Editorial Board, Molecular Conceptor, Synergix, Ltd., 2005 – Present  
Editorial Advisory Board, Current Topics in Medicinal Chemistry, Bentham, 2006 – 2009  
Editorial Board, Pharmacologyonline, 2006 – Present  
Editorial Board, Perspectives in Medicinal Chemistry, Libertas Academica, 2007 – Present



Editorial Board, The Open Medicinal Chemistry, Bentham, 2007 – Present  
Editorial Board, The Open Enzyme Inhibition Journal, Bentham, 2008 – Present  
Editorial Board, Current Bioactive Compounds, Bentham, 2008 – Present  
Editorial Board, Future Medicinal Chemistry, Future Science Group, 2008 – Present  
Senior Editor, Medicinal Chemistry Research, Springer, 2011 – Present  
Editorial Advisory Board, Journal of Medicinal Chemistry, ACS Publications, 2011 – Present  
Guest Editor, Current Topics in Medicinal Chemistry, Bentham, 2011  
Editorial Board, World Journal of Pharmacology, Baishideng Publishing Group, 2011 – Present  
Associate Editor (Ad Hoc), AAPS PharmSci Tech, AAPS Publishing, 2011  
Editorial Advisory Board, Letters in Drug Design and Discovery, Bentham, 2012 – 2015  
Editorial Board, Scientifica Pharmaceuticals, Hindawi Publishing Corporation, 2012 – Present  
Editorial Board of Referees, Arkivoc Journal, <http://www.arkat-usa.org>, 2012 – Present  
Editor-In-Chief (Ad Hoc), AAPS PharmSci Tech, AAPS Publishing, 2012  
Review Editor, Frontiers in Neuroscience, 2015 – Present

### **Expert Witness Legal Consultancy**

09/2007 – 03/2008 Sterne, Kessler, Goldstein & Fox, Washington, DC  
11/2012 – 4/2013 Kramer, Levin, Naftalis, & Frankel LLP, New York, NY  
03/2014 – present IMS Expert Services, Pensacola, FL  
03/2014 – 09/2015 Dechert LLP, Silicon Valley, CA  
03/2014 – present Palm Beach Law, PLLC, Delray Beach, FL

### **Scientific Consultancy**

West Virginia University, School of Pharmacy, 12/2011

## **PROFESSIONAL/COMMUNITY SERVICE**

### **Professional Service**

International Pharmaceutical Federation (FIP)

Co-chair, Drug Design and Discovery Special Interest Group, 2015 – present

Sigma Xi, Ole Miss Chapter

President Elect, 2006 – 2008

President, 2008 – 2010

Pharmacy Leadership and Education Institute, Glaxo/Smith Kline Albert Prescott Award  
selection committee, 2002 – 2006

American Association of Pharmaceutical Scientists (AAPS), Drug Design and Discovery Section  
(formerly Medicinal and Natural Products Section), 1997 – present

National Biotechnology Conference Planning Committee, 2003 – 2004

Vice-Chair, DDD section, 2005 – 2006

Chair-Elect, DDD section, 2006 – 2007

Annual Meeting Planning Committee, 2006 – 2007

Chair, DDD section, 2007 – 2009

Nominations committee, 2007 – 2009

Past-Chair, DDD Section 2009 – 2010

Program Coordination Committee, 2019 – 2010

AAPS D3I committee/focus group, 2008 – present

American Association of Pharmaceutical Scientists (AAPS) Publications Committee

Chair-Elect, 2010 – 2011

Chair, 2011 – 2012

Past Chair, 2012 – 2013

American Association of Pharmaceutical Scientists (AAPS) Annual Meeting Planning Committee

Drug Design and Discovery (DDD) Section representative, 2006 – 2007

Co-Chair, 2011 – 2012

Chair, 2012 – 2013

Past Chair, 2013 – 2014

American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference Planning Committee, DDD Section representative, 2003 – 2004

American Association of Pharmaceutical Scientists (AAPS) Executive Council

Member-At-Large, 2013 – 2016

President-Elect, 2016 – present

American Chemical Society Local Ole Miss Section Secretary, 2003 – 2004

## **UNIVERSITY ADMINISTRATION, COMMITTEES AND SERVICE**

### University of Mississippi

Chancellor's Standing Committee, University Research Board, School of Pharmacy Representative (alternate), 2013 – present

UM Southeastern Conference Faculty Achievement Award Selection Committee, 2012 – present

UM Faculty Achievement Award Selection Committee, 2012 – present

Chancellor's Standing Committee, Academic Freedom and Responsibility, 2011 – 2014

**Chair**, 2013-2014

Task Force on the UM World Science Festival, 2010 – 2011

Chancellor's Standing Committee, Graduate Council, 2009 – 2013

UM Competes Task Force, School of Pharmacy Representative, 2008

Sigma Xi, Ole Miss Chapter, President, 2008 – 2010

Sigma Xi, Ole Miss Chapter, President Elect, 2006 – 2008

Alcohol Task Force, 2006 – 2007

Vivarium Task Force, 2005

Faculty Senate, 2003 – 2005

**Chair**, University-wide elections committee, 2004 – 2005

National Center for Natural Products Research Assoc. Director Search Committee, 2003 – 2004

Faculty Achievement Award Selection Committee, 2002

Who's Who selection committee, 2001 – 2003

Chancellor's Committee on Health and Safety, Chemical Safety Subcommittee, 2001 – 2004

### University of Mississippi, School of Pharmacy

BioMolecular Sciences, Faculty Search Committee Chair, Neuropharmacology, 2015 – 2016

BioMolecular Sciences, Faculty Search Committee Member, Medicinal Chemistry, 2015 – 2016

Dean's Office, Grants Management Specialist Search Committee, 2014

BioMolecular Sciences, R & D Scientist Search Committee, 2014

Dean's Office, Accountant I Search Committee, 2014

Promotion/Tenure Track Ad Hoc Committee, Department of BioMolecular Sciences, 2014

Medicinal Chemistry Faculty Search Committee, 2013

Curriculum Committee, 2012 – present, **Chair**, 2014 – 2016  
Joseph Sam Alumni Award Selection Committee, 2011 – present  
Research and Graduate Affairs, 2008 – 2014  
Faculty Council, 2008 – 2010  
Continuing Education, Lecture, and Alumni Activities, **Vice-Chair**, 2007 – 2008  
Curriculum Subcommittee of Strategic Planning Committee, 2006 – 2007  
Faculty Council, **Chair**, 2006 – 2007  
Medicinal Chemistry Chair Search Committee, 2005 – 2006  
Scholastic Standards Committee, 2005 – 2007  
Pharmacology Faculty Search Committee, 2005  
Mission, Planning, and Assessment Subcommittee, ACPE accreditation team, 2004 – 2006  
Faculty Task Force on Faculty Governance, 2004 – 2005  
Coy Waller Distinguished Lecture Committee, 2004  
Faculty Council, **Vice-Chair**, 2004 – 2006  
Pharmaceutics Chair Search Committee, 2003 – 2005  
Medicinal Chemistry Faculty Search Committee, 2003 – 2004  
Medicinal Chemistry Faculty Search Committee, 2002 – 2003  
Early-Entry Program Interviewer, 2003 – present  
Faculty-Student Affairs Committee, 2001 – 2004  
Honors and Awards Committee, **Chair**, 2001 – 2003  
Curriculum Committee, 2001 – 2005  
Drug abuse advisory council, and Utah school advisor 2002 – present

University of Georgia, College of Pharmacy

Dean-Graduate Student Relations Committee, 1993  
Graduate Student Representative on Faculty Search Committee, 1991  
Research and Seminar Committee, Student Member, 1991 – 1992

Ohio Northern University

Student Senate, College of Pharmacy Representative, 1991 – 1993

Ohio Northern University, College of Pharmacy

Dean Search Committee, Student Representative, 1991  
Pharmacy Council, President, 1991 – 1992  
Drug Abuse Awareness Team, 1991

## PRESENTATIONS

### INVITED PRESENTATIONS

#### International Invited Presentations

- 07/16      **McCurdy, C.R.** Sigma receptor antagonists potentiate the analgesic effects of cannabinoid receptor agonists. Hungarian Academy of Sciences. Budapest, Hungary. July 4, 2016.
- 06/16      **McCurdy, C.R.** Sigma receptor blockade potentiates the analgesic effects of cannabinoids. 26<sup>th</sup> Annual Symposium of the International Cannabinoid Research Society. Bukovina, Poland. Oral presentation 21, June 27, 2016.
- 06/15      **McCurdy, C.R.** Sigma receptor antagonists in peripheral pain: Potential for improved diagnosis and pharmacotherapy with significantly reduced CNS liabilities. 46<sup>th</sup> International Narcotics Research Conference (INRC). Session 2 – “Advances in Therapeutic Design”. Phoenix, AZ. June 15-19, 2015.
- 12/11      **McCurdy, C.R.** The Other Side of the Desk: A Career in Academia. American Association of Pharmaceutical Scientists, Student-Postdoctoral Outreach and Development Webinar presentation (SPOD-4). December 8, 2011. (archived at <http://www.aaps.org/webinars>)
- 01/11      **McCurdy, C.R.** Investigations of *Mitragyna speciosa* as a potential treatment for Opioid Withdrawal Syndrome. Recent Advances in Pharmaceutical Research. Beni-Sueif University. Beni-Sueif, Egypt. January 12, 2011.
- 02/10      **McCurdy, C.R.** Development of highly selective sigma-2 receptor ligands. 2<sup>nd</sup> International Conference on Drug Design and Discovery, Dubai, United Arab Emirates (UAE). February 1-4, 2010 (WITHDREW PARTICIPATION).
- 09/09      **McCurdy, C.R.** Sigma Receptors as Targets for Cocaine and Methamphetamine Pharmacotherapies. Universidade of São Paulo, Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, Brazil. September 10, 2009.
- 09/09      **McCurdy, C.R.** Characterization of the opioid withdrawal effects of *Mitragyna speciosa*, 7<sup>th</sup> International Congress of Pharmaceutical Sciences (CIFARP), Centro de Convenções Ribeirão Preto SP Brazil, September 6-9, 2009.
- 07/09      **McCurdy, C.R.** Sigma receptors: applications to drug design. University of Bologna Summer School, Bologna, Italy, July 6-10, 2009.
- 06/09      **McCurdy, C.R.** Understanding sigma receptor ligand interactions. 71<sup>st</sup> Annual Meeting of The College on Problems of Drug Dependence (CPDD), Reno, NV, June 20-25, 2009.

- 11/08 **McCurdy, C.R.** Development of Selective Sigma Receptor Ligands. 2009 Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, GA, November 16-20, 2008.
- 11/08 **McCurdy, C.R.** Combining Target-based and Ligand-based Virtual Screening to Identify New Leads. 2009 Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, GA, November 16-20, 2008.
- 09/08 **McCurdy, C.R.** Design and Application of Selective Sigma Ligands. Universite Catholique de Louvain, Brussels, Belgium, September 9, 2008.
- 06/08 **McCurdy, C.R.** Discovery of a selective sigma-2 receptor ligand and the potential involvement of sigma-2 receptors in cocaine toxicity. 70<sup>th</sup> Annual Meeting of The College on Problems of Drug Dependence (CPDD), San Juan, Puerto Rico, June 14-19, 2008.
- 02/08 **McCurdy, C.R.** Sigma Receptor Ligands as Pharmacotherapy for Psychostimulant Abuse. 1<sup>st</sup> International Conference on Drug Design and Discovery, Dubai, United Arab Emerites (UAE). February 4-7, 2008.
- 07/07 **McCurdy, C.R.** Salvinorin A Binding Mode at Kappa Opioid Receptors and Reversal of Actions by Kappa Antagonists. International Narcotics Research Conference (INRC), Berlin, Germany, July 8-13, 2007.
- 06/07 **McCurdy, C.R.** New approaches to the treatment of psychostimulant abuse. Peking Union Medical College, Chinese Academy of Medical Science, Institute of Materia Medica, Beijing, China, June 1, 2007.
- 04/07 Singh, N.; **McCurdy, C.R.** Delineating a powerful virtual screening protocol for G-protein coupled receptors: Application to a selective kappa opioid receptor agonist, salvinorin A. Pharmaceutical Sciences World Congress, Amsterdam, Netherlands, April 22-25, 2007.
- 06/04 **McCurdy, C.R.** Novel templates with affinity for opioid receptors. Institut de Chimie Pharmaceutique Albert Lespagnol, Universite de Lille 2, Lille, France, June 10, 2004.
- 06/04 **McCurdy, C.R.** Salvinorin A, A Structurally Novel Opioid Lead. Universite Paul Sabatier, Toulouse III, CNRS, Toulouse, France, June 8, 2004.
- 06/04 **McCurdy, C.R.** Non-nitrogenous kappa opioid receptor ligands based on Salvinorin A, a unique and naturally occurring opiate lead. Journées Franco Belges, Luxembourg, June 3, 2004.
- 06/04 **McCurdy, C.R.** Parallel Synthesis of Spirohydantoin Libraries. Universite Catholique de Louvain, Brussels, Belgium, June 1, 2004.
- 07/03 **McCurdy, C.R.** Design and application of reporter affinity labels. Universita di

Catania, Catania, Italy. July 14, 2003.

### **National Invited Presentations**

- 1/16        **McCurdy, C.R.** Targeting Sigma Receptors to Diagnose and Treat Peripheral Pain. College of Pharmacy, Department of Medicinal Chemistry, University of Florida, Gainesville, FL (January 5, 2016)
- 12/15        **McCurdy, C.R.** Improving the diagnosis and treatment of peripheral pain. College of Pharmacy, Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR (December 4, 2015)
- 9/15        **McCurdy, C.R.** Sigma Receptor Antagonists for Peripheral Pain. College of Pharmacy, Center for Drug Design, University of Minnesota, Minneapolis, MN (September 16, 2015)
- 1/15        **McCurdy, C.R.** Chemical Dependency Awareness Day Lecture, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA (January 7, 2015)
- 12/14        **McCurdy, C.R.** Developing Pharmacotherapy for Psychostimulant Abuse and Peripheral Pain. University of Mississippi Medical Center, Jackson, MS (December 11, 2014)
- 12/14        **McCurdy, C.R.** Development of Highly Selective Sigma Receptor Ligands for CNS Disorders. Department of Medicinal and Natural Products Chemistry Seminar Series, College of Pharmacy, University of Iowa, Iowa City, IA (December 9, 2014)
- 06/14        **McCurdy, C.R.** Development and Preclinical Efficacy of a Dual Sigma Receptor Antagonist/Dopamine Uptake Inhibitor, CM699, as a Medication for Stimulant Abuse. Featured Speaker, Drug Discovery and Development Colloquium 2014. University of Arkansas for Medical Sciences, Little Rock, AR. (June 20, 2014)
- 12/13        **McCurdy, C.R.** The Utilization of Natural Products as Potential Treatments for Drug Abuse and Addiction, Division of Clinical Chemistry/Hematology, University of Pittsburgh Medical Center Presbyterian-Shadyside. Pittsburgh, PA. (December 17, 2013)
- 03/13        **McCurdy, C.R.** The Role of Sigma-1 Receptors in Cocaine Self-Administration. Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University Medical Center, Stanford, CA. (March 12, 2013).
- 11/12        **McCurdy, C.R.** Medicinal Chemistry Careers as a Pharmacist. Ohio Northern University, Raabe College of Pharmacy, Ada, OH. (November 7, 2012).
- 05/12        **McCurdy, C.R.** Targeting Sigma Receptors - Insights to blocking the actions of psychostimulants and CNS disorders. University of Georgia, Department of

Pharmaceutical and Biomedical Sciences, College of Pharmacy, Athens, GA.  
(May 9, 2012)

- 04/12 **McCurdy, C.R.** Towards the Development of a Botanical Drug Product for Opioid Withdrawal Syndrome. University of Georgia Symposium on Pharmaceutical Development. The Classic Center, Athens, GA. (April 19, 2012)
- 06/11 **McCurdy, C.R.** Sigma Receptors: Targeting an Enigma? Philip S. Portoghese Symposium - Recognizing 50 years of Teaching, Research and Service. University of Minnesota, College of Pharmacy, Minneapolis, MN. (June 2, 2011)
- 4/11 **McCurdy, C.R.** Investigations of Kratom (*Mitragyna speciosa*) as a potential herbal drug for opioid withdrawal. West Virginia University, School of Pharmacy, AAPS Visiting Scholar Speaker, Morgantown, WV. (April 7, 2011)
- 12/10 **McCurdy, C.R.** *Mitragyna speciosa* (Kratom): Development of a botanical product for opioid addiction. Duquesne University, Mylan School of Pharmacy, Graduate School of Pharmaceutical Sciences, Pittsburgh, PA. (December 1, 2010)
- 09/10 **McCurdy, C.R.** Investigations of Kratom (*Mitragyna speciosa*) as a potential herbal drug for opioid withdrawal. West Virginia University, School of Pharmacy Research Day, Keynote Speaker, Morgantown, WV. (September 30, 2010) (Rescheduled – personal health issue)
- 04/10 **McCurdy, C.R.** Highly Selective Sigma Receptor Ligands as Antipsychostimulants. University of Tennessee Health Science Center, Department of Pharmaceutical Sciences Seminar Series, Memphis, TN. (April 12, 2010)
- 11/09 **McCurdy, C.R.** Development of Highly Selective Sigma-2 Receptor Ligands. Department of Health & Human Services, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program Seminar Series. Baltimore, MD (November 17, 2009)
- 01/09 **McCurdy, C.R.** Drug Design of Potential Treatments for Cocaine and Methamphetamine Abuse. The University of Georgia, Department of Chemistry, Athens, GA (January 15, 2009)
- 05/08 **McCurdy, C.R.** Design of a highly selective sigma-2 receptor ligand with cocaine antagonist activity. University of Maryland School of Pharmacy, Baltimore, MD. (May 28, 2008)
- 04/08 **McCurdy, C.R.** *Mitragyna speciosa*. 4<sup>th</sup> Interim American Society of Pharmacognosy Meeting, National Center for Natural Products Research, Oxford, MS. (April 12-16, 2008)

- 12/07 **McCurdy, C.R.** Sigma Receptor Antagonists with Anti-Psychostimulant Activity, McLean Hospital, Harvard Medical School, Belmont, MA. (December 17, 2007)
- 09/07 **McCurdy, C.R.** Sigma Receptor Antagonists as Potential Pharmacotherapy for Psychostimulant Abuse, University of Kentucky, College of Pharmacy, Lexington, KY. (September 28, 2007)
- 09/07 **McCurdy, C.R.** Guest Speaker, Contemporary Pharmacy Practice Course, Ohio Northern University, College of Pharmacy, Ada, OH. (September 26, 2007)
- 09/07 **McCurdy, C.R.** Pharmacotherapy Development for Cocaine and Methamphetamine Abuse. Ohio Northern University, College of Pharmacy, Ada, OH. (September 26, 2007)
- 04/07 **McCurdy, C.R.** Novel Pharmacological Interventions for Psychostimulant Abuse: Answering NIDAs Call. University of Minnesota National Institute on Drug Abuse Training Grant Retreat. Minneapolis, MN. (April 9, 2007).
- 02/07 **McCurdy, C.R.** Targeting Sigma Receptors for the Treatment of Cocaine Abuse. University of Arkansas, College of Pharmacy, Little Rock, AR. (February 9, 2007).
- 12/06 **McCurdy, C.R.** A New Approach to Pharmacotherapies for Psychostimulant Abuse. Southern Illinois University Edwardsville, Department of Pharmaceutical Sciences, School of Pharmacy, Edwardsville, IL. (December 8, 2006).
- 10/06 **McCurdy, C.R.** Sigma Receptor Antagonists: Potential Pharmacotherapy for Psychostimulant Abuse. University of Houston, Department of Pharmaceutical Sciences, Houston, TX. (October 3, 2006)
- 10/05 Singh, N.; Cheve, G.; **McCurdy, C.R.** Comparative Protein Modeling of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase Enzyme from *Plasmodium falciparum*: Structural and Docking Analysis. American Chemical Society Prospectives: Advances in Structure-Based Drug Discovery, October 16-19, Philadelphia, PA.
- 10/05 **McCurdy, C.R.** Sigma Receptor Ligands. University of Minnesota, College of Pharmacy, Department of Medicinal Chemistry, Minneapolis, MN. (October 18, 2005)
- 11/04 **McCurdy, C.R.**, Scully, S.S. "Natural Products (Naturceuticals) with Analgesic Properties", NIDA-AAPS Naturceuticals (Natural Products), Nutraceuticals, Herbal Botanicals, and Psychoactives: Drug Discovery and Drug-Drug Interactions. November 5-7, 2004. Baltimore, MD.
- 05/04 **McCurdy, C.R.** "Medicinal Chemistry Research: Keys to the Future", Ohio Northern University, College of Pharmacy, Ada, OH.



- 04/04 **McCurdy, C.R.** “Efforts to Understand Opioid Receptor Selectivity”, Department of Medicinal Chemistry, University of Florida, College of Pharmacy, Gainesville, FL.
- 03/04 **McCurdy, C.R.** “Drug Discovery Processes and the Art of Medicinal Chemistry” University of Florida, College of Dentistry, Comprehensive Center for Pain Research, Gainesville, FL.
- 03/01 **McCurdy, C.R.** "Naphthalene Dicarboxaldehyde Derivatives of Opiate Antagonists as Reporter Affinity Labels: A New Concept in Medicinal Chemistry.” University of Mississippi, School of Pharmacy, University, MS.
- 02/01 **McCurdy, C.R.** “Reporter Affinity Labels: A New Concept in Medicinal Chemistry.” University of the Pacific, College of Pharmacy, Stockton, CA.
- 03/98 **McCurdy, C.R.** “Synthesis and biological activity of lobeline analogs with selective activation of neuronal nicotinic receptors containing the  $\beta$ -4 subunit. University of Minnesota, College of Pharmacy, Minneapolis, MN.
- 09/97 Beach, J.W.; **McCurdy, C.R.**; Terry Jr., A.V.; Cosford, N. “Nicotinic agonists based on lobeline, synthesis and biological evaluation. 214<sup>th</sup> ACS National Meeting, Las Vegas, NV.

## PRESENTATIONS (Not published as abstracts)

### National/International Presentations

- 07/16 Mottinelli, M.; Journigan, V.B.; Mesangeau, C.; Cutler, S.J.; Eans, S.O.; Medina, J.M.; McLaughlin, J.P.; **McCurdy, C.R.** New Biphenylmethylenepiperidine Derivatives as Dual Opioid-NPFF Ligands: In Vitro and In Vivo Evaluation. International Narcotics Research Conference, Bath, United Kingdom, July 11-14, 2016. M1.13
- 10/15 Mavlyutov, T.A.; Yao, A.; Chu, U.; Chu, M.; Zhao, L.; Yang, H.; **McCurdy, C.R.**; Ruoho, A.E.; Guo, L.-W. Role of sigma receptors in the viability of retinal pigment epithelial cells – studies using the crispr-cas9 system. Neuroscience 2015, Society for Neuroscience, Chicago, IL, October 17-21, 2015. 58.10/J21
- 10/15 Ruoho, A.E.; Mavlyutov, T.A.; Chu, U.B.; Chu, M.; Zhao, L.; Yang, H.; **McCurdy, C.R.**; Guo, L.-W. Sigma-2 receptor 18 kDa and PGRMC1 are distinct gene products. Neuroscience 2015, Society for Neuroscience, Chicago, IL, October 17-21, 2015. 555.03
- 10/15 Nicholson, H.E.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. A potential neuroprotective function for the sigma-2 receptor. Neuroscience 2015, Society for Neuroscience, Chicago, IL, October 17-21, 2015. 555.07

- 06/15 McLaughlin, J.P.; Eans, S.O.; Medina, J.M.; Ganno, M.L.; Journigan, V.B.; Cutler, S.J.; **McCurdy, C.R.** Neuropeptide FF (NPFF)-induced hyperalgesia and acute opioid antinociceptive tolerance is prevented by VBJ-192, a dual-activity mu-opioid receptor (MOR) agonist-NPFF receptor antagonist. 46<sup>th</sup> International Narcotics Research Conference (INRC). Phoenix, AZ. June 15-19, 2015. Poster #68.
- 11/14 Hiranita, T.; Kopajtic, T.A.; Mesangeau, C.; **McCurdy, C.R.**; Katz, J.L. Self-administration of the sigma-receptor agonist, DTG, in experimentally naïve rats. Neuroscience 2014, Society for Neuroscience, Washington DC, November 15-19, 2014. 812.02/BB23
- 11/14 Nicholson, H.E.; Weledji, N.T.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Metabolism stimulation by CM-769: A novel function for the sigma-2 receptor. Neuroscience 2014, Society for Neuroscience, Washington DC, November 15-19, 2014. 299.17/B31
- 11/14 Alsharif, W.; Kopajtic, T.; Kandasamy, M.; Avery, B.A.; Hiranita, T.; Katz, J.L.; **McCurdy, C.R.** Analogs of the Dual Sigma Receptor Antagonist Dopamine Uptake Inhibitor, CM699, as Potential Pharmacotherapy for Stimulant Abuse. 2014 American Association of Pharmaceutical Scientists Annual Meeting, San Diego, CA. November 2-6, 2014. Poster # T3020. **AAPS DDDI Graduate Student Research Award Presentation**
- 07/14 **McCurdy, C.R.**; Journigan, V.B.; Mesangeau, C.; Kapanda, C.N.; Cutler, S.J.; Eans, S.O.; Ganno, M.L.; Mollereau, C.; McLaughlin, J.P. Synthesis and Evaluation of Dual-Activity Opioid-NPFF Ligands for Receptor Affinity, Antinociception and Tolerance Liabilities. 45<sup>th</sup> meeting of the International Narcotics Research Conference 2014. Montreal, Quebec, Canada. July 13-18, 2014. Poster #25.
- 06/14 **McCurdy, C.R.**; Mesangeau, C.; Hiranita, T.; Lopez, J.; Brellenthin, A.; Kopajtic, T.; Coggiano, M.; Alsharif, W.; Jamalapuram, S.; Tsai, S.-Y.; Avery, B.A.; Su, T.-P.; Tanda, G.; Katz, J.L. Development and Preclinical Efficacy of a Dual Sigma Receptor Antagonist/Dopamine Uptake Inhibitor, CM699, as Potential Pharmacotherapy for Stimulant Abuse. Drug Discovery and Development Colloquium 2014, Little Rock, AR, June 20-21, 2014. **Featured Speaker Address.**
- 06/14 Alsharif, W.; Kopajtic, T.; Kandasamy, M.; Avery, B.A.; Hiranita, T.; Katz, J.L.; **McCurdy, C.R.** Analogs of the Dual Sigma Receptor Antagonist/Dopamine Uptake Inhibitor, CM699, as Potential Pharmacotherapy for Stimulant Abuse. Drug Discovery and Development Colloquium 2014, Little Rock, AR, June 20-21, 2014. Poster # 6.
- 06/14 Alsharif, W.; Comeau, A.; Mesangeau, C.; Bowen, W.D.; **McCurdy, C.R.** Development of Selective Irreversible Ligands for Sigma-2 Receptors. Drug

Discovery and Development Colloquium 2014, Little Rock, AR, June 20-21, 2014. Oral Presentation.

- 06/14 **McCurdy, C.R.**; Journigan, V.B.; Mesangeau, C.; Kapanda, C.N.; Cutler, S.J.; Eans, S.O.; Ganno, M.L.; Mollereau, C.; McLaughlin, J.P. Synthesis and Evaluation of Dual-Activity Opioid-NPFF Ligands for Receptor Affinity, Antinociception and Tolerance Liabilities. NIH, NIGMS Fifth Biennial National IDeA Symposium of Biomedical Research Excellence (NISBRE), Washington, DC, June 16-18.
- 06/14 Avery, B.A.; Jamalapuram, S.; **McCurdy, C.R.** Determination of CM699, a Sigma Receptor Ligand, in Rat Plasma by UPLC/MS and its Application to a Pharmacokinetic Study. NIH, NIGMS Fifth Biennial National IDeA Symposium of Biomedical Research Excellence (NISBRE), Washington, DC, June 16-18.
- 04/14 Katz, J.L.; Hiranita, T.; Lopez, J.; Brellenthin, A.; Mesangeau, C.; Alsharif, W.; Kopajtic, T.; Coggiano, M.; Jamalapuram, S.; Tsai, S.-Y.; Avery, B.A.; Su, T.-P.; Tanda, G.; **McCurdy C.R.** Preclinical Efficacy of the Dual Sigma Receptor Antagonist Dopamine Uptake Inhibitor, CM699, as a Medication for Stimulant Abuse. Experimental Biology 2014, San Diego, CA, April 26-30, 2014. 803.3/D382. Featured on the blog DRUG MONKEY April 28, 2014 <http://scientopia.org/blogs/drugmonkey/2014/04/28/will-a-dual-sigma-receptor-antagonist-dopamine-transporter-inhibitor-treat-stimulant-abuse/>
- 04/14 Hiranita, T.; Kopajtic, T.; Mesangeau, C.; Narayanan, S.; **McCurdy, C.R.**; Katz, J.L. The Dopamine Uptake Inhibitor, WIN 35,428 Has Sigma2 Receptor Agonist Effects that Contribute to its Self-Administration. Experimental Biology 2014, San Diego, CA, April 26-30, 2014. 14-3880-EB
- 11/13 Avery, B.A.; Jamalapuram, S.; Mesangeau, C.; Alsharif, W.; **McCurdy, C.R.** Determination of CM699, a Sigma Receptor Ligand, in Rat Plasma by Ultra Performance Liquid Chromatography Mass Spectrometry and its Application to a Pharmacokinetic Study. 2013 Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, November 10-14, 2013. W4298
- 11/13 **McCurdy, C.R.**; Alsharif, W.; Comeau, A.; Mesangeau, C.; Bowen, W.D. Synthesis and Identification of Novel and Selective Irreversible Sigma-2 Ligands. 2013 Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, November 10-14, 2013. M1005
- 11/13 Nicholson, H.; Comeau, A.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Irreversible modulators of sigma-2 receptor function: Isothiocyanate derivatives of SN-79. Neuroscience 2013, Society for Neuroscience, San Diego, CA, November 9-13, 2013. 63.03/EE9
- 11/13 Matsumoto, R.R.; Robson, M.J.; **McCurdy, C.R.**; Coop, A.; Kaushal, N. Amphetamine and Related Drugs: Neural Mechanisms of Action. Neuroscience

2013, Society for Neuroscience, San Diego, CA, November 9-13, 2013.  
Nanosymposium 213; 213.07

- 04/13 Nicholson, H.; Comeau, A.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Development of selective irreversible antagonists for sigma-2 receptors. American Association for Cancer Research 2013 Annual Meeting, Washington, DC, April 6-10, 2013. 13-A-6261-AACR
- 10/12 Comeau, A.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Development of selective irreversible affinity ligands for sigma-2 receptors. Neuroscience 2012, Society for Neuroscience, New Orleans, LA, October 13-17, 2012. 61.13/N16
- 10/12 Matsumoto, R.R.; Seminerio, M.J.; Hansen, R.; Kaushal, N.; **McCurdy, C.R.**; Zhang, H.-T. The evaluation of AZ66, an optimized sigma receptor ligand, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. Neuroscience 2012, Society for Neuroscience, New Orleans, LA, October 13-17, 2012. 354.31/T18
- 10/12 Robson, M.; **McCurdy, C.R.**; Matsumoto, R.R. Methamphetamine elicits PERK-mediated endoplasmic reticulum transcriptional responses in NG108-15 Cells. Neuroscience 2012, Society for Neuroscience, New Orleans, LA, October 13-17, 2012. 360.12/Z8
- 10/12 Hiranita, T.; Mereu, M.; Tanda, G.; Kopajtic, T.A.; Mesangeau, C.; **McCurdy, C.R.**; Katz, J.L. Combined dopamine transporter and  $\sigma$  receptor actions: Effects of  $\sigma$  receptor subtype. Neuroscience 2012, Society for Neuroscience, New Orleans, LA, October 13-17, 2012. 561.19/U19
- 10/12 Alsharif, W.; Mesangeau, C.; Matsumoto, R.R.; Seminerio, M.J.; Robson, M.; Poupaert, J.H.; Amata, E.; **McCurdy, C.R.** Preparation and evaluation of a series of indoles as sigma receptor ligands. 2012 Annual Meeting of the American Association of Pharmaceutical Scientists, Chicago, IL, October 14-18, 2012.
- 10/12 Avery, B.A.; Vuppala, P.K.; Jamalapuram, S.; Furr, E.B.; **McCurdy, C.R.** Determination of 7-hydroxymitragyine, a  $\mu$ -opioid receptor agonist, in rat plasma by UPLC/MS/MS and its application to a pharmacokinetic study. 2012 Annual Meeting of the American Association of Pharmaceutical Scientists, Chicago, IL, October 14-18, 2012.
- 10/12 Avery, B.A.; Vuppala, P.K.; Jamalapuram, S.; Furr, E.B.; **McCurdy, C.R.** Pharmacokinetics of 7-hydroxymitragyine, a  $\mu$ -opioid receptor agonist, in male Sprague Dawley rats. 2012 Annual Meeting of the American Association of Pharmaceutical Scientists, Chicago, IL, October 14-18, 2012.
- 08/12 Shih, J.; Xie, J.J.; Mesangeau, C.; Fazio, N.; Seminerio, M.; Xu, Y.; Matsumoto, R.R.; **McCurdy, C.R.** Investigation of piperazine derivatives as sigma receptor ligands with methamphetamine antagonist activity. 244<sup>th</sup> American Chemical Society National Meeting, Philadelphia, PA, August 19-23, 2012. MEDI-372.

- 08/12 Xie, J.J.; Shih, J.; Mesangeau, C.; Seminerio, M.; Xu, Y.; Matsumoto, R.R.; **McCurdy, C.R.** Selective sigma-2 receptor ligands derived from tetrahydroisoquinolone. 244<sup>th</sup> American Chemical Society National Meeting, Philadelphia, PA, August 19-23, 2012. MEDI-373.
- 07/12 Avery, B.A.; Vuppala, P.K.; Jamalapuram, S.; Furr, E.B.; **McCurdy, C.R.** Pharmacokinetics of 7-hydroxymitragynine, a m-opioid receptor agonist, in male Sprague Dawley rats. 43<sup>rd</sup> International Narcotics Research Conference (INRC), Kansas City, MO, July 15-20, 2012.
- 10/11 Jamalapuram, S.; Vuppala, P.K.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. In Vitro Metabolic Stability and Pharmacokinetics in Lead Optimization of Novel Sigma Receptor Ligands. 2011 Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, DC, October 23-27, 2011.
- 10/11 Jamalapuram, S.; Vuppala, P.K.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Determination of AZ66, a Metabolically Stable Sigma Receptor Ligand, in Rat Plasma by Ultra-Performance Liquid Chromatography Mass Spectrometry and its Application to Pharmacokinetic Study. 2011 Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, DC, October 23-27, 2011. **\*AWARDED AN APQ SECTION TRAVEL GRANT**
- 10/11 Vuppala, P.K.; Jamalapuram, S.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Preclinical Characterization of CM301, a Novel and High Affinity Sigma-1 Receptor Ligand with Potent Anti-Cocaine Actions. 2011 Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, DC, October 23-27, 2011.
- 10/11 Vuppala, P.K.; Jamalapuram, S.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Metabolism of CM304, a Novel Highly Selective Sigma-1 Receptor Antagonist with Potent Anti-Cocaine Actions, in Mouse, Rat and Human Liver Microsomes and Characterization of Metabolites by UPLC/MS/MS. 2011 Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, DC, October 23-27, 2011.
- 11/10 Vinnakota, H.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Pharmacokinetic and Tissue Distribution Studies of SN79, a Sigma-2 Receptor Ligand, in Rats using UPLC/MS/MS. 2010 FIP Pharmaceutical Sciences World Congress / Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, November 14-18, 2010.
- 11/10 Vinnakota, H.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Method Development and Validation of a Novel Sigma-2 Receptor Ligand (SN79) in Rat Plasma by UPLC/MS/MS and its Application to Pharmacokinetics in Rats. 2010 FIP Pharmaceutical Sciences World Congress / Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, November 14-18, 2010.

- 11/10 Jamalapuram, S.; Vuppala, P.K.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Determination of CM156, a Selective Sigma Receptor Ligand, in Rat Plasma by Ultra-Performance Liquid Chromatography Mass Spectrometry and its Application to Pharmacokinetic Study. 2010 FIP Pharmaceutical Sciences World Congress / Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, November 14-18, 2010.
- 11/10 Boddu, S.P.; Furr, E.B.; Cutler, S.J.; **McCurdy, C.R.**; Avery, B.A. Pharmacokinetics of Kratom Tea Extracts in Sprague Dawley Rats. 2010 FIP Pharmaceutical Sciences World Congress / Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, November 14-18, 2010.
- 09/10 James, M.; Shen, B.; Nielsen, C.; Zavaleta, C.; Berganos, R.A.; Mesangeau, C.; Gambhir, S.S.; **McCurdy, C.R.**; Chin, F.T. A New Ultra Selective PET Probe for Imaging Sigma-1 Receptors in Living Subjects. 2010 World Molecular Imaging Congress, Kyoto, Japan, September 8-11, 2010.
- 09/10 Shen, B.; Leblanc, G.; Subbarayan, M.; Berganos, R.A.; Mesangeau, C.; **McCurdy, C.R.**; Gambhir, S.S.; Chin, F.T. A Small Microwave Unit to Enhance Commercial Radiochemistry Modules for Making  $^{18}\text{F}$ -labeled Imaging Agents. 2010 World Molecular Imaging Congress, Kyoto, Japan, September 8-11, 2010.
- 07/10 James, M.L.; Shen, B.; Zavaleta, C.; Nielsen, C.H.; Berganos, R.A.; Mesangeau, C.; Shaikh, J.; Gambhir, S.S.; Matsumoto, R.R.; **McCurdy, C.R.**; Chin, F.T. [ $^{18}\text{F}$ ]FTC-146: A Novel and Highly Selective PET Ligand for Visualizing Sigma-1 Receptors in Living Subjects. 2010 Neuroreceptor Mapping Congress, Glasgow, Scotland, July 22-24, 2010.
- 07/10 El-Alfy, A.; Wilson, L.; Furr, E.B.; Song, Y.; Cutler, S.J.; Boddu, S.P.; Avery, B.A.; Boyer, E.W.; **McCurdy, C.R.** Blockade of Opioid Withdrawal Syndrome by Orally Administered Lyophilized Kratom (*Mitragyna speciosa*) Tea and Mitragynine in Mice. 41<sup>st</sup> International Narcotics Research Conference (INRC), Malmo, Sweden, July 11-16, 2010.
- 07/10 Avery, B.A.; Boddu, S.P.; Furr, E.B.; Cutler, S.J.; **McCurdy, C.R.** Pharmacokinetics of Kratom Tea Extracts in Sprague Dawley Rats. 41<sup>st</sup> International Narcotics Research Conference (INRC), Malmo, Sweden, July 11-16, 2010.
- 03/10 Abdelazeem, A.H.; Mesangeau, C.; Khan, S.; Sufka, K.J.; White, S.W.; Abbas, S.E.S.; Poupaert, J.H.; **McCurdy, C.R.** Design, Synthesis and Biological Evaluation of 2-(3*H*)-benzoxazolone and 2-(3*H*)-benzothiazolone dimers as potential anti-inflammatory agents. 239<sup>th</sup> ACS National Meeting, San Francisco, CA, March 21-25, 2010.

- 11/09 Vinnakota, H.; Vuppala, P.; Leon, J.F.; Furr, E.B.; Adkins, J.E.; Cutler, S.J.; **McCurdy, C.R.**; Avery, B.A. Pharmacokinetic and Tissue Distribution Studies of Mitragynine, A Naturally Occurring Opioid Agonist, In Rats Using UPLC/MS/MS. 2009 Annual Meeting of the American Association of Pharmaceutical Scientists, Los Angeles, CA, November 8-12, 2009.
- 7/09 **McCurdy, C.R.**; Habib, E.; Leon, J.F.; Adkins, J.E.; Furr, E.B.; Polgar, W.E.; Toll, L.; Cutler, S.J. Chemical and Pharmacological Characterization of Kratom (*Mitragyna speciosa*). 40<sup>th</sup> International Narcotics Research Conference (INRC), Portland, OR, July 12-16, 2009.
- 7/09 El-Alfy, A.; Wilson, L.; Furr, E.B.; Adkins, J.E.; Leon, J.F.; Cutler, S.J.; **McCurdy, C.R.** Characterization of the Neurobehavioral Effects of Kratom (*Mitragyna speciosa*). 40<sup>th</sup> International Narcotics Research Conference (INRC), Portland, OR, July 12-16, 2009.
- 7/09 Avery, B.A.; Vinnikota, H.; Leon, J.F.; Furr, E.B.; Adkins, J.E.; Cutler, S.J.; **McCurdy, C.R.** Pharmacokinetic and Tissue Distribution Studies of Mitragynine, a Naturally Occurring Opioid Agonist, in Rats using UPLC/MS/MS. 40<sup>th</sup> International Narcotics Research Conference (INRC), Portland, OR, July 12-16, 2009.
- 3/09 Kaushal, N.; Croom, C.; Shaikh, J.; Narayanan, S.; Mesangeau, C.; Poupaert, J.H.; **McCurdy, C.R.**; Matsumoto, R.R. SN79, a novel sigma-2 receptor antagonists, attenuates the behavioral effects of cocaine in mice. Behavior, Biology and Chemistry: Translational Research in Addiction, University of Texas Health Science Center, San Antonio, TX, March 20-22, 2009.
- 11/08 Nolan, T.L.; Singh, N.; **McCurdy, C.R.** New potential leads for the development of kappa opioid ligands using a hybrid virtual screening approach. 2008 Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, GA, November 16-20, 2008.
- 7/08 Yekkirala, A.S.; Lunzer, M.M.; **McCurdy, C.R.**; Powers, M.D.; Roerig, S.C.; Portoghesi, P.S. NNTA, a Selective Activator of Heterodimeric Mu/Kappa Opioid Receptors Produces no Tolerance or Physical Dependence in Mice. 39<sup>th</sup> International Narcotics Research Conference (INRC), Charleston, SC, July 13-18, 2008.
- 06/08 Cui, J.; Leon, J.F.; Mesangeau, C.; Peres, B.; Adkins, J.E.; Furr, E.B.; Arribas, M.; Nolan, T.L.; Cutler, S.J.; Polgar, W.E.; Toll, L.; **McCurdy, C.R.** Studies on the determination of the pharmacophoric elements of the naturally occurring opioid receptor agonist, mitragynine and related alkaloids from *Mitragyna speciosa*. 70<sup>th</sup> Annual Meeting of The College on Problems of Drug Dependence (CPDD), San Juan, Puerto Rico, June 14-19, 2008.
- 11/07 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Yu, J.; Diers, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Novel Pharmacologic Interventions for Cocaine

Abuse. 2007 Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, CA, November 11-15, 2007. **AWARDED podium presentation in the 2007 AAPS Graduate Student Symposium in Drug Design and Discovery sponsored by Bristol-Myers Squibb**

- 11/07 Adkins, J.E.; Moraes, N.; White, N.; Tadlock, L.A.; Nieto, M.J.; **McCurdy, C.R.** HPLC method for determination of mitragynine, an indole alkaloid, in crude extracts of *Mitragyna speciosa*. 2007 Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, CA, November 11-15, 2007.
- 11/07 Yekkirala, A.S.; **McCurdy, C.R.**; Lunzer, M.M.; Powers, M.D.; Portoghese, P.S. Naphthoyl-b-naltrexamine (NNTA) selectively activates kappa/mu opioid receptor heterodimers: an insightful tool to study novel mechanisms of analgesia. Neuroscience 2007, Society for Neuroscience, San Diego, CA, November 3-8, 2007. 119.1. (oral presentation)
- 11/07 Shaikh, J.; Wilson, L.L.; Mesangeau, C.; **McCurdy, C.R.**; Poupaert, J.H.; Matsumoto, R.R. CM156, a novel sigma receptor ligand, attenuates the locomotor stimulant and neurotoxic effects of methamphetamine in mice. Neuroscience 2007, Society for Neuroscience, San Diego, CA, November 3-8, 2007. 173.5/GG19.
- 08/07 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Design, synthesis and evaluation of the first highly selective sigma-2 receptor ligand. 234<sup>th</sup> American Chemical Society National Meeting, Boston, MA, August 19-23, 2007. MEDI-335.
- 07/07 Adkins, J.; Moraes, N.; White, N.; Tadlock, L.A.; Nieto, M.J.; **McCurdy, C.R.** HPLC method for determination of mitragynine, an indole alkaloid, in crude extracts of *Mitragyna speciosa*. International Narcotics Research Conference (INRC), Berlin, Germany, July 8-13, 2007.
- 06/07 Matsumoto, R.R.; Wilson, L.L.; Mesangeau, C.; Diers, J.; Shaikh, J.; Poupaert, J.H.; **McCurdy, C.R.** CM156, a novel substituted piperazine, attenuates the behavioral effects of cocaine in mice. The College on Problems of Drug Dependence, Qubec, Canada, June 16-21, 2007.
- 03/07 Singh, N.; Mesangeau, C.; Narayanan, S.; Shaikh, J.; Matsumoto, R.R.; **McCurdy, C.R.** Development of the first predictive pharmacophore models for sigma-1 and sigma-2 receptor antagonists. 233<sup>rd</sup> American Chemical Society National Meeting, Chicago, IL, March 25-29, 2007. MEDI-292.
- 10/06 Adkins, J.E.; Tadlock, L.A.; Nieto, M.J.; **McCurdy, C.R.** Isolation, purification and identification of indole alkaloids from *Mitragyna speciosa* with simultaneous determination by LC methods. 2006 Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, October 29 – November 2, 2006.



- 10/06 Singh, N.; **McCurdy, C.R.** A 3D structure of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase enzyme from *Mycobacterium tuberculosis*: Homology modeling and Docking analysis. 2006 Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, October 29 – November 2, 2006.
- 10/06 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Yu, J.; Diers, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Design, synthesis and biological evaluation of novel heterocyclic compounds as sigma receptor antagonists. 2006 Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, October 29 – November 2, 2006.
- 10/06 Shaikh, J.; Yu, J.; Diers, J.A.; Narayanan, S.; Mesangeau, C.; **McCurdy, C.R.**; Matsumoto, R.R. Evaluation of novel 2(3H)-benzoxazolones and 2(3H)-benzothiazolones against cocaine-induced behavior in mice. Neuroscience 2006, Society for Neuroscience, Atlanta, GA, October 14-18, 2006. 189.9/MM78.
- 09/06 Adkins, J.E.; Nieto, M.J.; **McCurdy, C.R.** Studies toward synthetically determining a pharmacophore of mitragynine, an indole alkaloid from *Mitragyna speciosa*: Removal of C-ring. 232<sup>nd</sup> American Chemical Society National Meeting, San Francisco, CA, September 10-14, 2006. MEDI-535.
- 09/06 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Yu, J.; Diers, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Design, synthesis and evaluation of original 2(3H)-benzoxazolones and 2(3H)-benzothiazolones as highly potent sigma receptor antagonists. 232<sup>nd</sup> American Chemical Society National Meeting, San Francisco, CA, September 10-14, 2006. MEDI-462.
- 09/06 Singh, N.; Cheve, G.; **McCurdy, C.R.** Three dimensional chemical-feature-based pharmacophore development for kappa opioid receptor agonist. 232<sup>nd</sup> American Chemical Society National Meeting, San Francisco, CA, September 10-14, 2006. MEDI-456.
- 03/06 Singh, N.; Cheve, G.; Narayanan, S.; Ferguson, D.M.; **McCurdy, C.R.** A Combined Ligand-Based and Target-Based Approach for the Identification of Novel Lead Structures: Application to Salvinorin A, a Selective Kappa Opioid Receptor Agonist. 213<sup>th</sup> American Chemical Society National Meeting, Atlanta, GA, March 26-31, 2006.
- 11/05 **McCurdy, C.R.**; Sufka, K.J.; Warnick, J.E.; Nieto, M.J. Salvinorin A, a kappa opioid receptor agonist, is an ultra short acting analgesic. 35<sup>th</sup> Annual Meeting of the Society for Neuroscience, Washington, DC, November 12-18, 2005.
- 07/05 **McCurdy, C.R.**; Sufka, K.J.; Warnick, J.E.; Nieto, M.J. Salvinorin A, a kappa opioid receptor agonist, is an ultrashort acting analgesic. 36<sup>th</sup> International Narcotics Research Conference, Annapolis, MD, July 10-15, 2005.

- 10/04 Warnick, J.E.; Feltenstein, M.W.; **McCurdy, C.R.**; Sufka, K.J. The role of opiate receptor subtypes in social attachment in young domestic fowl. 34<sup>th</sup> Annual Meeting of the Society for Neuroscience, San Diego, CA, Oct. 23-27, 2004. Program No. 762.2.
- 09/04 **McCurdy, C.R.**; Sufka, K.J.; Warnick, J.E.; Nieto, M.J. Salvinorin A, a kappa opioid receptor agonist, is a fast acting, potent analgesic. AAPS-NIDA Symposium: Frontiers in Science: Drug Addiction-From Basic Research to Therapies. National Institutes of Health Campus, Bethesda, MD, September 9-11, 2004. Poster number 20.
- 03/04 Nieto, M.J.; Philip, A.E.; Mirbagheri, A.; **McCurdy, C.R.** Solution-Phase Parallel-Synthesis of Hydantoin Derivatives. 227<sup>th</sup> American Chemical Society National Meeting, Anaheim, CA, March 28-April 1. ORGN-337
- 03/04 Kane, B.E.; **McCurdy, C.R.**; Ferguson, D.M. Molecular Interactions of salvinorin A at the kappa opioid receptor. 227<sup>th</sup> American Chemical Society National Meeting, Anaheim, CA, March 28-April 1. MEDC-273
- 09/03 Zhang, Y.; **McCurdy, C.R.**; Portoghese, P.S. Synthesis and kinetic studies of agonist and antagonist reporter affinity labels for opioid receptors. 226<sup>th</sup> American Chemical Society National Meeting, New York, NY, September 7-11. MEDC-153.
- 07/03 Stewart, J.; Dayan, F.E.; **McCurdy, C.R.**; Zjawiony, J.K. Studies on the biosynthesis of the novel  $\kappa$ -opioid agonist, salvinorin A. 44<sup>th</sup> Annual Meeting of the American Society of pharmacognosy. Chapel Hill, NC, July 12-16.
- 07/03 **McCurdy, C.R.**; Nieto, M.; Kane, B.; Ferguson, D.M. Studies directed toward understanding the opioid receptor recognition of Salvinorin A, a non-nitrogenous natural product with kappa opioid receptor selectivity. 34<sup>th</sup> International Narcotics Research Conference, Perpignan, France, July 7-11, 2003.
- 07/03 Zhang, Y.; **McCurdy, C.R.**; Portoghese, P.S. Kinetic studies of covalent association of agonist and antagonist reporter affinity labels with opioid receptors. 34<sup>th</sup> International Narcotics Research Conference, Perpignan, France, July 7-11, 2003.
- 03/03 Vangapandu, S.; Phillip, A.; Stewart, J.D.; Zjawiony, J.; Avery, M.A.; **McCurdy, C.R.** Progress toward the total synthesis of salvinorin A: A potent, non-nitrogenous  $\kappa$ -opioid receptor selective agonist. 225<sup>th</sup> American Chemical Society National Meeting, New Orleans, LA, March 23-27. ORGN-421.
- 07/02 Zhang, Y.; **McCurdy, C.R.**; Metzger, T.G.; Portoghese, P.S. Studies of wild type and mutant mu opioid receptors with fluorogenic reporter affinity labels using flow cytometry: evidence for cross-linking K233 and C235. 33<sup>rd</sup> International Narcotics Research Conference, Pacific Grove, CA.

- 04/01 **McCurdy, C.R.**; LeBourdonnec, B.; El Kouhen, R.; Portoghese, P.S. Second generation reporter affinity labels: Naphthalene dicarboxaldehyde derivatives of  $\beta$ -naltrexamine. 221<sup>st</sup> ACS National Meeting, San Diego, CA.
- 03/00 **McCurdy, C.R.**; Jones, R.M.; Portoghese, P.S.; Investigation of phenolic bioisosterism in opioids: Synthesis and biological evaluation of 3-methylsulfonamide analogues of naltrexone and oxymorphone. 219<sup>th</sup> ACS National Meeting, San Francisco, CA.
- 03/98 **McCurdy, C.R.**; Beach, J.W.; Smith, J.B.; Cutler, S.J. Behavioral and discriminative stimulus effects of cholinergic channel modulators. 215<sup>th</sup> ACS National Meeting, Dallas, TX.
- 06/98 Metting T.L., Burgio D.E., Terry Jr. A.V., Beach J.W. **McCurdy C.R.** and Allen D.D. Assessment of blood-brain barrier (BBB) choline transport inhibition by lobeline and arecoline derivatives using the *in situ* rat brain perfusion technique. Presentation at the Merck Undergraduate Research Seminar, Estes Park, CO.
- 04/97 **McCurdy, C.R.**; Venkateshwaran, T.G.; Stewart, J.T.; Beach, J.W. Chiral separations of lobeline analogs using high performance capillary electrophoresis and derivatized cyclodextrins as chiral additives. 213<sup>th</sup> ACS National Meeting, San Francisco, CA.
- 11/96 Carl, G.F.; Williamson, R.; Beach, J.W.; **McCurdy, C.R.**; Pauly, J.R.; Sparks, J.A.; Terry Jr., A.V. Lobeline and analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Society for Neuroscience National Meeting, Washington, DC.
- 08/96 Beach, J.W.; **McCurdy, C.R.**; Terry Jr., A.V.; Pauly, J.R.; Boss, K.L. Nicotinic agonists based on lobeline. 212<sup>th</sup> ACS National Meeting, Orlando, FL.
- 08/95 Beach, J.W.; **McCurdy, C.R.**; Terry Jr., A.V.; Templeton, R.E. Analogues of lobeline as potential nicotinic agonists. 210<sup>th</sup> ACS National Meeting, Chicago, IL.

### Regional Presentations

- 06/15 Alsharif, W.; Kopajtic, T.; Kandasamy, M.; Avery, B.A.; Hiranita, K.; Katz, J.L.; **McCurdy, C.R.** Synthesis, Biological Evaluation, and Metabolic Stability Enhancement of the dual Sigma Receptor Antagonist/DAT Inhibitor Agents as Potential Pharmacotherapy for Stimulant Abuse. Drug Discovery and Development Colloquium 2015, June 22-24, 2015, Oxford, MS
- 05/13 Gogineni, V.; Leon, J.F.; Wilson, L.L.; Avery, B.A.; **McCurdy, C.R.**; Cutler, S.J. *Mitragyna speciosa*: Isolation & Pharmacological Evaluation of the Indole

Alkaloids. 40<sup>th</sup> Annual MALTO Medicinal Chemistry and Pharmacognosy Meeting, May 19-21, Little Rock, AR

- 05/12 Alsharif, W.; Mesangeau, C.; Amata, E.; Seminerio, M.J.; Robson, M.J.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Synthesis and Pharmacological Evaluation of Indole-based Sigma Receptor Ligands. 39<sup>th</sup> Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 20-22, Monroe, LA
- 09/11 El-Alfy, A.; Wilson, L.L.; Furr, E.B.; Boddu, S.P.; Avery, B.A.; Cutler, S.J.; Boyer, E.W.; **McCurdy, C.R.** Blockage of opioid withdrawal syndrome by orally administered lyophilized kratom (*Mitragyna speciosa*) tea and mitragynine in mice. NS19. 2011 South East Regional IDeA Meeting, September 22-24, 2011, New Orleans, LA (Poster and selected for invited **ORAL PODIUM** Presentation)
- 09/11 Avery, B.A.; Boddu, S.P.; Furr, E.B.; Cutler, S.J.; **McCurdy, C.R.** Pharmacokinetics of kratom tea (*Mitragyna speciosa*) extracts in Sprague Dawley rats. NS3. 2011 South East Regional IDeA Meeting, September 22-24, 2011, New Orleans, LA
- 09/07 Xu, Y.; Shaikh, J.; Viard, E.; Fishback, J.; Kaushal, N.; Mesangeau, C.; Narayanan, S.; Poupaert, J. H.; **McCurdy, C.R.**; Matsumoto, R.R. Synthesis and Evaluation of Subtype Selective Sigma Receptor Ligands From Substituted 2(3*H*)-Benzoxazolone and 2(3*H*)-Benzothiazolone Derivatlves. 2007 South Central Chapter of the Society of Toxicology Meeting, September 27-28, 2007, Oxford, MS
- 05/07 Narayanan, S.; Mesangeau, C.; Shaikh, J.; Yu, J.; Diers, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Design, synthesis and biological evaluation of novel sigma receptor antagonists as anti-cocaine agents. 34<sup>th</sup> Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 20-22, 2007, Monroe, LA
- 05/07 Adkins, J.E.; Moraes, N.V.; While, N.; Tadlock, L.A.; Nieto, M.J.; **McCurdy, C.R.** HPLC Method Validation for Determination of Mitragynine, an Indole Alkaloid, in Crude Extracts of *Mitragyna speciosa*. 34<sup>th</sup> Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 20-22, 2007, Monroe, LA
- 05/06 Singh, N.; Cheve, G.; **McCurdy, C.R.** Combination of Molecular Modeling, Site-Directed Mutagenesis, and SAR Studies to Delineate a Robust Virtual Screening Protocol: Application to Salvinorin A. 33<sup>rd</sup> Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 21-23, 2006, Houston, TX
- 05/06 Vyas, N.; Mollereau, C.; Cheve, G.; **McCurdy, C.R.** Design, Synthesis and Biological Evaluation of Small Molecules for Neuropeptide FF Receptors. 33<sup>rd</sup> Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 21-23, 2006, Houston, TX

- 11/05 Singh, N.; Cheve, G.; **McCurdy, C.R.** Probing the structure of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase Enzyme from *Plasmodium falciparum*: Comparative Protein Modeling and Docking Studies. Southeast Regional American Chemical Society Meeting. November, 1-4, Memphis, TN.
- 05/05 Philip, A.E.; Geldenhuys, W.J.; Lockman, P.R.; McAfee, J.H.; Miller, B.L.; Allen, D.D.; **McCurdy, C.R.** Inhibition of Choline Uptake by N-cyclohexylcholine, a High Affinity Ligand for the Choline Transporter at the Blood-Brain Barrier. 32<sup>nd</sup> Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 22-24, Oxford, MS
- 05/05 Singh, N.; **McCurdy, C.R.** 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase: A Novel Target for Development of Broad-Spectrum Antimicrobial and Antiprotozoal Drug Candidates. 32<sup>nd</sup> Annual MALTO Medicinal Chemistry and Pharmacognosy meeting, May 22-24, Oxford, MS
- 05/04 Philip, A.E.; Nieto, M.J.; Mirbagheri, A.; Poupaert, J.H.; **McCurdy, C.R.** Application of Solution-Phase Parallel Synthesis to Preparation of Spirohydantoin Derivatives. 31<sup>st</sup> Annual MALTO meeting, University of Tennessee Health Sciences Center, Memphis, TN.
- 05/03 Philip, A.E.; McAfee, J.H.; Lockman, P.R.; Roder, K.E.; Allen, D.D.; **McCurdy, C.R.** Probing the structural requirements of the blood brain barrier choline transporter through synthetic choline analogues. 30<sup>th</sup> Annual MALTO meeting, University of Arkansas, Little Rock, AR.
- 04/02 Zhang, Y.; **McCurdy, C.R.**; Metzger, T.G.; Portoghese, P.S. Design of fluorogenic reporter affinity labels for kinetic studies of opioid receptor cross-linking using flow cytometry. 40<sup>th</sup> Annual MIKI Meeting, University of Illinois at Chicago, Chicago, IL
- 04/01 **McCurdy, C.R.**; Le Bourdonnec, B.; El Kouhen, R.; Portoghese, P.S. Second generation reporter affinity labels: analogs of  $\beta$ -Naltrexamine. 39<sup>th</sup> Annual MIKI Meeting, Minneapolis, MN
- 04/00 **McCurdy, C.R.**; Jones, R.M.; Portoghese, P.S. Investigation of phenolic bioisosterism in opiates. MIKI Meeting, Iowa City, IA
- 06/96 Venkateshwaran, T.G.; **McCurdy, C.R.**; Stewart, J.T.; Beach, J.W. Enantiomeric separation of lobeline analogues using capillary electrophoresis: Effects of cyclodextrin additives. South Eastern Regional Meeting of the American Association of Pharmaceutical Scientists, Research Triangle Park, NC.
- 05/95 **McCurdy, C.R.**; Beach, J.W.; Terry Jr.; Wargo, H.L.; Templeton, R.E. Synthesis and receptor binding of N-Substituted-2-styryl-1,2,3,6-tetrahydropyridine as a potential nicotinic agonists. 22<sup>nd</sup> Annual MALTO Meeting, Xavier University, New Orleans, LA.

**Local Presentations**

- 05/09      **McCurdy, C.R.** Utilization of Natural Products in the Treatment of Drug Abuse. NIH COBRE Community Outreach Program, The University of Mississippi, University, MS. (May 11, 2009)
- 03/09      **McCurdy, C.R.** Developing Treatments for Drug Abuse. Keynote Speaker. Mississippi Junior Science and Humanities Symposium. The University of Mississippi, University, MS. (March 8, 2009)
- 09/07      **McCurdy, C.R.** Sigma Receptors and Psychostimulants. Department of Pharmacognosy, School of Pharmacy, University of Mississippi, University, MS. (September 11, 2007)
- 03/07      Narayanan, S.; Mesangeau, C.; Shaikh, J.; Yu, J.; Diers, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Design, Synthesis and Biological Evaluation of Novel Sigma Receptor Antagonists as Anti-Cocaine Agents. Sigma Xi Research Day, University of Mississippi, University, MS, March 26, 2007. (**AWARDED BEST POSTER IN TWO CATEGORIES**)
- 04/06      Singh, N.; Cheve, G.; Narayanan, S.; Ferguson, D.M.; **McCurdy, C.R.** . A Combined Ligand-Based and Target-Based Approach for the Identification of Novel Lead Structures: Application to Salvinorin A, a Selective Kappa Opioid Receptor Agonist. Sigma Xi Research Day, University of Mississippi, University, MS, April 4, 2006. (**AWARDED BEST POSTER**)
- 09/04      **McCurdy, C.R.**; Sufka, K.J.; Warnick, J.E.; Nieto, M.J. Antinociceptive Profile of Salvinorin A, a Structurally Unique Kappa Opioid Agonist. National Center for Natural Products Research, School of Pharmacy, Internal Poster Session. University of Mississippi, University, MS.
- 05/04      Warnick, J.E.; Feltenstein, M.W.; **McCurdy, C.R.**; Sufka, K.J. The Role of Opiate Receptor Subtypes in Social Attachment in Young Domestic Fowl. Sigma Xi Research Day, University of Mississippi, University, MS
- 05/04      Philip, A.E.; Nieto, M.J.; Mirbagheri, A.; Poupaert, J.H.; **McCurdy, C.R.** Application of Solution-Phase Parallel Synthesis to Preparation of Spirohydantoin Derivatives. Sigma Xi Research Day, University of Mississippi, University, MS.
- 05/02      Zhang, Y.; **McCurdy, C.R.**; Metzger, T.G.; Portoghese, P.S. Reporter Affinity Labels: A single-molecular fluorogenic probe to cross-link opioid receptors studied via flow cytometry. Chemical Biology, A Single Molecular Perspective – NIH Molecular Biophysics, Biotechnology, and Chemistry-Biology Interface Joint Training Grant Symposium, University of Minnesota, Minneapolis, MN
- 05/02      Zhang, Y.; **McCurdy, C.R.**; Metzger, T.G.; Portoghese, P.S. Kinetic studies of opioid receptors cross-linking with fluorogenic reporter affinity labels using flow

cytometry. The 2<sup>nd</sup> Symposium on Targets and Cellular Mechanisms Involved in Drug Addiction, University of Minnesota, Minneapolis, MN

- 01/99 **McCurdy, C.R.**; Portoghese, P.S. Rational design and synthesis of  $\delta$ -opioid receptor affinity labels. NIDA Neuroscience Training Grant Retreat, University of Minnesota, Minneapolis, MN.
- 10/96 Venkateshwaran, T.G.; **McCurdy, C.R.**; Stewart, J.T.; Beach, J.W. Enantiomeric separation of lobeline analogs using capillary electrophoresis. Graduate Research Day, University of Georgia, Athens, GA.
- 05/95 **McCurdy, C.R.**; Beach, J.W.; Terry Jr., A.V.; Wargo, H.L.; Templeton, R.E. Synthesis and nicotinic receptor binding of N-substituted-2-styryl-1,2,3,6-tetrahydropyridine. Graduate Research Day, University of Georgia, Athens, GA.

**LECTURES AND TEACHING EXPERIENCE:**University of Mississippi, School of Pharmacy, University, MS.

04/14-Present	PHAR 332: Basic Pharmaceutics II. PY1 Professional Program Required Course. Taught one lecture on radiopharmaceuticals.
01/11-Present	MEDC 418: Chemical Neuroscience Principles of Drugs of Abuse. PY2 Professional Pharmacy Elective course (1 semester hour, spring semesters).
01/07-Present	MEDC 417: Medicinal Chemistry of Therapeutic Agents II. Undergraduate Level Professional Pharmacy Program. New course format in 2006-2007 to pharmacy program (3 semester hours, spring semesters).
01/07-Present	MEDC 502: Advanced Medicinal Chemistry II. Graduate Level course (3 semester hours, spring semesters).
08/06-Present	MEDC 416: Medicinal Chemistry of Therapeutic Agents I. Undergraduate Level Professional Pharmacy Program. New course format in 2006 to pharmacy program (3 semester hours, fall semesters)
08/06-Present	MEDC 501: Advanced Medicinal Chemistry I. Graduate Level course. (3 semester hours, fall semesters)
01/04-05/09	MEDC 541/542: Special Topics in Medicinal Chemistry: Drugs, Society, and Human Behavior. Undergraduate/Graduate pharmacy elective (3 semester hours)
02/03-05/05	PHCY 201: Use and Misuse of Drugs. Undergraduate level University-Wide Elective. Gave 2 (75 minute) lectures on CNS Depressants and Hallucinogens. (3 semester hours)
01/03-05/06	MEDC 314: Principles of Medicinal Chemistry. Undergraduate Level Professional Pharmacy Program. Teaching. (3 semester hours).
01/03-05/06	MEDC 315: Principles of Medicinal Chemistry Laboratory. Undergraduate level professional Pharmacy Program. Developed new laboratory program and teaching. (1 semester hour).
08/02-12/05	MEDC 503: Medicinal Chemistry Research Methodology. Graduate level. Redesigned and taught course. (3 semester hours).
01/02-Present	MEDC 713: Peripheral and Central Nervous System Agents. Graduate level. Developed and teaching course. (3 semester hours)
03/02-05/06	MEDC 412: Medicinal Chemistry. Gave 4 lectures on Narcotic analgesics. (3 semester hours)
01/02	PHCY 201: Use and Misuse of Drugs. Gave 2 (75 minute) lectures on Designer Drugs. (3 semester hours)

University of Georgia, College of Pharmacy, Athens, GA.

09/97	PHR 404: Medicinal Chemistry II. Central Nervous System Agents. Course for 2nd year pharmacy students. I gave one lecture on Alzheimer's Disease and Acetylcholinesterase inhibitors.
04/97	PHR 305: Biochemistry of Drugs and Disease. Course for 1st year pharmacy students. I gave 3 lectures on vitamins.
01/95-05/95	Laboratory Instructor: PHR 311: Medicinal Chemistry Laboratory. Undergraduate Pharmacy students.



## GRANT ACTIVITY

### Pending

**NIH R15 DA042406-01A1**, NIDA “Rational Design of Opioids Lacking P-glycoprotein Activity”, Co-Investigator (Mercer, PI). Submitted October 25, 2016.

**NIH R21 DAXXXXXX-01**, NIDA “Developmental Toxicity of Cannabidiol and  $\Delta^9$ -Tetrahydrocannabinol”, Co-Investigator (Willett, PI), PA-14-162. Submitted October 12, 2016.

**DoD PR161310** “Sigma receptor ligands as non-opioid based pain management”. Principal Investigator (20% effort, 2.4 calendar months), Mechanism/Announcement: CDMRP W81XWH-16-PRMRP-IIRA. Partnering PI, Jay McLaughlin, University of Florida. Submitted October 19, 2016. Peer review: December 2016.

**NIH P30 GM122733-01**, NIGMS “Phase III Center of Biological Research Excellence”, Principal Investigator (45% effort, 5.4 calendar months), PAR-14-178 Limited Competition: Centers of Biomedical Research Excellence. Submitted May 25, 2016. Reviewed November 2, 2016. Priority Score: 46.

**NIH R01 DA042488-01**, NIDA “Novel pharmacotherapy for peripheral pain with significantly reduced liabilities”, Principal Investigator (25% effort, 3 calendar months), PAR-13-048 Drug Discovery for Nervous System Disorders. Submitted under continuous submission privilege November 18, 2015. Priority Score 47; 28<sup>th</sup> percentile.

### Currently Active

**NIH R01 DA0391167-01A1**, NIDA “Deterrents for prescription opioid abuse”, Co-Investigator (Freeman, PI), PA13-015. Submitted March 5, 2015. Priority Score 20; 8<sup>th</sup> percentile. **(FUNDED)**. Total costs year 1: \$301,396.

**NIH R01 DA034777-03**, NIDA “Optimization of non-peptide probes for Neuropeptide FF receptors”, Principal Investigator (25% effort, 3 calendar months), PAR-12-060 “Solicitation of validated hits for the discovery of in vivo chemical probes”. Submitted March 5, 2013. **(FUNDED)**. Priority Score 32, 16<sup>th</sup> Percentile). Total Costs as Submitted \$2,161,110. Review group: NIDA ZRG1-MDCN-C (58), June 21, 2013. Funded Project Period: September 15, 2014 – August 31, 2017. Total costs funded: **\$ 1,486,100**. Total costs year 1: \$498,705. Total costs year 2: \$485,817. Total costs year 3: \$489,241.

**NIH P20 GM104932-10**, NIGMS, “Center for Research Excellence in Natural Products Neuroscience” Principal Investigator **(FUNDED)** September 24, 2012 – August 31, 2017. Total costs year 6; \$1,871,576. Total costs year 7; \$2,099,508. Total costs year 8; \$2,063,370. Total costs year 9; \$2,045,714. Total costs year 10; \$2,006,361.

**DAA2-15-61222-1**, U.S. Department of Agriculture “Isolation and Biological Evaluation of Opioid Receptor Modulators from *Asteraceae* Plants Growing in Egypt”, Principal Investigator.

**Completed**

**NIH R01 DA023205** NIDA, “Novel Pharmacologic Interventions for Drugs of Abuse”, Principal Investigator (25% time, 3 calendar months), (**FUNDED**) Submitted June 1, 2006. **\$1,250,000** direct cost. Review group: NIDA Special Emphasis Panel ZDA1 RXL-E (11), October 4, 2006. Priority Score 157 on 1<sup>st</sup> submission (23.3<sup>rd</sup> percentile). April 9, 2007 – March 31, 2012. Total costs year 1; \$355,949. Total costs year 2; \$349,075. Total costs year 3; \$349,075. Total costs year 4; \$345,584. Total costs year 5; \$311,025 + \$24,192. In no-cost extension from April 1, 2012 – March 31, 2013. **COMPLETED**

**NIH R03 DA029738**, ECHEM NIDA, “Non-peptide ligands for NPFF receptors”, Co-Investigator (5% time, 0.6 cal mo), PAS-07-327 **\$353,110** total costs. Submitted October 16, 2009. (**FUNDED**) (Priority Score 42 on 1<sup>st</sup> submission). July 1, 2010 – June 30, 2012. Total costs year 1; \$176,555. Total costs year 2; \$171,259. **COMPLETED**

**NIH COBRE, 1 P20 RR021929**, NCCR, “Center for Research Excellence in Natural Products Neuroscience” Co-Investigator, submitted for review Oct. 20, 2004. **\$11,000,000 total. \$750,000** direct cost to my lab (Rae Matsumoto, PI). **FUNDED** (50% time). Priority score 152 on 1<sup>st</sup> submission. Total costs year 1; \$188,986. Total costs year 2; \$199,699. **COMPLETED**

**NSF/IGERT grant 0333136** from the University of Mississippi and the University of Southern Mississippi. “Entrepreneurship at the Interface of Polymer Science and Medicinal Chemistry” Co-PI (Lon Mathias, PI) 08/03-07/08. **\$3,600,000 total costs. COMPLETED**

**NIH R03 DA017360**, NIDA Small Grants Program DA017360-01. “Salvinorin A: A novel opioid agonist lead” Principal Investigator, 01/04-01/06. **\$140,673**, total costs (funded 9/30/03, priority score 169 on 1<sup>st</sup> submission) **COMPLETED**

**CDC grant U01 CI000211** “Development and Testing of New Antimalarial Drugs.” Co-Investigator (M. Avery, PI). August 1, 2004 - July 31, 2009. **\$3,000,000/year** total costs. **COMPLETED**

**CDC grant U50/CCU423310**, “Development and Testing of New Medicines for Treatment of Emerging Infectious Diseases.” Co-Investigator (M. Avery, PI). September 15, 2003 – September 14, 2006. **COMPLETED**

**CDC grant U50/CCU418839-02, \$50,000/year.** “Development and Testing of New Medications for the Treatment of Emerging Infectious Diseases.” Co-investigator (M. Avery, PI). September 15, 2002- September 14, 2005. **COMPLETED**

**CDC grant UR3/CCU418652-02, \$80,000/year.** “Development and Testing of New Antimalarial Drugs”. Co-investigator (M. Avery, PI). August 31, 2002- June 30, 2005. **COMPLETED**

**American Association of Colleges of Pharmacy New Investigator Award.** “Molecular Modeling, Design, Synthesis and Biological Evaluation of Novel Nociceptin/ Orphanin FQ (N/OFQ) Receptor Ligands. Principal Investigator. December 15, 2002-December 15, 2003. **\$10,000. COMPLETED**

**University of Mississippi, Faculty small grant award.** “Design and Synthesis of ORL-1 Receptor Ligands” Principal Investigator. April 16, 2002-April 16, 2003. **\$5,000. COMPLETED**

Research Training Award, National Institute on Drug Abuse, University of Minnesota, Minneapolis, MN. 07/98-07/01. \$86,000 salary support. \$4,500 materials support.

University of Georgia, College of Pharmacy. Pre-doctoral teaching assistantship award. 08/94-05/98, salary support.

**Submitted – Not awarded**

**NIH R21/R33 DA041507-01A1**, NIDA “Development of New GABA-B Receptor Agonists for Drug Addiction”, Co-Investigator (Colby, PI). Submitted March 15, 2016.

**NSF EPSCoR 1632856**, “RII Track-2 FEC: Improving Learning and Memory in Juveniles: Environmental Enrichment Strategies and Cognitive Enhancers.” Co-Investigator (Coolen, PI). Submitted February 4, 2016.

**NIH R15 DA042406-01**, NIDA “Rational Design of Opioids Lacking P-glycoprotein Activity”, Co-Investigator (Mercer, PI). Submitted October 25, 2015. ZRG1 MDCN-R (86). Priority Score 49 (Not Funded).

**NIH R21/R33 DA041507-01**, NIDA “Development of New GABA-B Receptor Agonists for Drug Addiction”, Co-Investigator (Colby, PI). Submitted June 16, 2015. (Not Discussed).

**NIH R01 DA040669-01**, NIDA “Hit-to-Lead Optimization Studies of Cannabinoid Receptor 2 (CB2) Agonists Discovered Through In Silico Virtual Screening”, Co-Investigator (Doerksen, PI), PA-13-302. Submitted February 5, 2015. (Not Discussed).

**NIH R01 DA0391167-01**, NIDA “Deterrents for prescription opioid abuse”, Co-Investigator (Freeman, PI), PA13-015 BRLE review group. Submitted June 5, 2014. Impact score:40 Percentile 37. (Not Funded)

NIH R21 GRANT11586190, NINDS “A New Sigma-1 Receptor Antagonist to Diagnose Chronic Pain Generators”, Principal Investigator (5% effort, 0.6 calendar months) on Sub-Contract to Stanford University (Biswal, PI), PA-13-303 “NIH Exploratory/Developmental Research Grant Program.” Submitted February 17, 2014. (Not Funded).

NIH R01 DA039392-01 GRANT11669797, NIDA “Non-Peptide Ligands for NPF Receptors”, Principal Investigator (25% effort, 3 calendar months), PAR-13-048 “Drug Discovery for Nervous System Disorders (R01).” Submitted June 5, 2014. (**WITHDRAWN**).

NIH R21, NINDS, “A New Sigma-1 Receptor Antagonist to Diagnose and Treat Chronic Pain Generators”, Principal Investigator (5% effort, 0.6 calendar months) on Sub-Contract to Stanford University (Biswal, PI), PA-11-261 “NIH Exploratory/Developmental Research Grant Program.” Submitted February 15, 2013. (not funded)

NIH R01, NIDA, "Pharmacology of MDPV and related bath salts. Co-Investigator, Consortium with Temple University, submitted June 5, 2012 in response to PA-10-268 (Liu-Chen & Rawls, PIs) (not funded)

NIH R21, "Novel Diagnostic Agents for Imaging Sigma-1 Receptor Drug Therapy in Alzheimer's Disease. Co-Investigator, Consortium with Stanford University, submitted February 16, 2012 in response to PAR-11-100 (Chin, PI) (not funded)

NIH R01 DA034777-01, NIDA, "Optimization of non-peptide probes for the Neuropeptide FF receptor system", Principal Investigator, submitted February 7, 2012 in response to PAR-12-060 (not funded)

NIH R01 DA030971-01, NIDA, "Development of Sigma Ligands as Antispycho stimulant Drugs", Principal Investigator (25% time, 3 cal mo), RFA-DA-10-018. **\$4,887,984** total costs. Submitted April 29, 2010 (not funded)

NIH R21/R33 DA029967-01, NIDA, "Selective Sigma-2 Receptor Ligands", Principal Investigator (25% time, 3 cal mo), RFA-DA-10-005 **\$1,800,277** total costs. Submitted December 4, 2009; (Priority Score 39, not funded)

NIH RC1 GM091443, NIGM, "Selective Sigma-2 Receptor Probes", Principal Investigator (25% time, 3 cal mo), Submitted April 24, 2009. **\$986,219** total costs. Broad Challenge Area (06) Enabling Technologies and Specific Challenge Topic. 06-GM-102: Chemist/biologist collaborations facilitating tool development. RFA-OD-09-003 (not funded)

NIH, R01 DA023205-03S1 competitive revision to **DA023205**, NIDA, "Lead Optimization of Anti-psychostimulants", Principal Investigator (25% time, 3 cal mo), Submitted April 21, 2009. **\$1,028,858** total costs. NOT-OD-09-058 (not funded)

NIH R01 DA025775-01, NIDA, "Opioids derived from Kratom, a psychoactive botanical", Principle Investigator (25% time, 3 cal mo), Submitted February 5, 2008. **\$1,250,000** direct costs. PA-07-374 (not funded)

NIH R21, NINDS, "Prolylcarboxypeptidase Dysfunction in Stroke", Co-Investigator (5% time, 0.6 cal mo), submitted for review June, 2007. (not funded)

NIH R01 DA023939-01, NIDA, "Novel Pharmacologic Interventions for Psychostimulant Abuse", Principle Investigator (25% time, 3 cal mo), (**WITHDRAWN**) Submitted January 25, 2007. \$1,250,000 direct cost. RFA-DA-07-006. Review group: NIDA Special Emphasis Panel ZDA1 MXS-M (17).

NIH R03, NIDA, "The pharmacokinetics of Salvia divinorum, an emerging hallucinogen", Co-Investigator (K. Babu, Harvard, PI). Submitted June 1, 2005. 2% time/salary (not funded)

NIH R01, NIDA, "Opioid Ligands Based on Salvinorin A" Principal Investigator, Submitted for review Oct. 1, 2004. \$1,250,000 direct cost. (not funded)

NIH R01, Consortium grant with Reza Mehvar at Texas Tech University Health Sciences Center, Amarillo, TX. Co-Investigator, 01/04-01/09. \$100,000 (not funded)

NIH RFA, NIGMS, 1 P50 GM067025-01, "Chemical Methodologies and Library Development Centers" Co-PI (M. Avery, UM, PI). Submitted February 1, 2002. **\$2,526,094** (not funded)

NIH COBRE, NCCR, Grant with Chemistry Department, Co-PI (D. Graves, UM, PI) Submitted February 2002. (not funded).

## **PROFESSIONAL DEVELOPMENT**

- 06/12 University of Utah School on Alcoholism and Other Drug Dependencies. Salt Lake City, UT. June 17-22, 2012
- 01/12-03/12 ACS Shortcourse on Pharmacokinetics and Pharmacodynamics. On-line (webinar) format, 6 one-hour lectures.
- 03/09 CITI Collaborative Institutional Training Initiative Course in the Responsible Conduct of Research, Office of Research and Sponsored Programs, The University of Mississippi, on-line
- 08/05-07/06 Academic Leadership Fellows Program, American Association of Colleges of Pharmacy.
- 10/04 National Association of Boards of Pharmacy, Foreign Pharmacy Graduate Equivalency Examination Item Writing Workshop. Park Ridge, IL.
- 09/00-12/00 Pharmacology of Drugs of Abuse, National Institute on Drug Abuse Training Grant Course, University of Minnesota, Department of Neuroscience.
- 09/00 Responsible conduct of research course. Office of Research, University of Minnesota.

**BIBLIOGRAPHY****INVITED SCIENTIFIC REVIEWS (PEER REVIEWED):**

1. Mankus, J.V.; **McCurdy, C.R.** Non-Peptide Ligands of Neuropeptide FF: Current Status and Structural Insights. *Future Medicinal Chemistry*, **2012**, *4*, 1085-1092. DOI: 10.4155/fmc.12.67 PMID: 22709252 PMCID: PMC3606921
2. Ward, J.; Rosenbau, C.; Herson, C.; **McCurdy, C.R.**; Boyer, E.W. Herbal Medicine for the Management of Opioid Addiction: Safe and Effective Alternatives to Conventional Pharmacotherapy? *CNS Drugs*, **2011**, *25*, 999-1007. Web Published 12-1-2011. DOI: 10.2165/11596830-000000000-00000. PMID: 22133323
3. Adkins, J.E.; Boyer, E.W.; **McCurdy, C.R.** *Mitragyna Speciosa*, a Psychoactive Tree From Southeast Asia. *Current Topics in Medicinal Chemistry*, **2011**, *11*, 1165-1175. Web Published 5-1-2011. DOI: 10.2174/156802611795371305 PMID: 21050173
4. Narayanan, S.; Mesangeau, C.; Poupaert, J.H.; **McCurdy, C.R.** Sigma Receptors and Cocaine Abuse. *Current Topics in Medicinal Chemistry*, **2011**, *11*, 1128-1150. Web Published 5-1-2011. DOI: 10.2174/156802611795371323 PMID: 21050176
5. Narayanan, S.; Bhat, R.; Mesangeau, C.; Poupaert, J.H.; **McCurdy, C.R.** Early Development of Sigma Receptor Ligands. *Future Medicinal Chemistry*, **2011**, *3*, 79-94. DOI: 10.4155/FMC.10.279 PMID: 21428827
6. Vyas, N.; Mollereau, C.; Cheve, G.; **McCurdy, C.R.** Structure Activity Relationships of Neuropeptide FF and Related Peptidic and Non-Peptidic Derivatives. *Peptides*, **2006**, *27*, 990-996. Web Published 2-21-2006. DOI: 10.1016/j.peptides.2005.07.024 PMID: 16490282
7. **McCurdy, C.R.**, Scully, S.S. Analgesic Substances Derived from Natural Products (Naturceuticals). *Life Sciences*, **2005**, *78*, 476-484. Web Published 10-10-2005. DOI: 10.1016/j.lfs.2005.09.006 PMID: 16216276
8. Philip, A.E.; Poupaert, J.H.; **McCurdy, C.R.** Opioid Receptor Like-1 (ORL1) molecular "road map" to understanding ligand interaction and selectivity. *Current Topics in Medicinal Chemistry*, **2005**, *5*, 325-340. DOI: 10.2174/1568026053544489 PMID: 15857315

**SCIENTIFIC PUBLICATIONS (PEER REVIEWED):**

1. Wilson, L.L.; Morris, J.; Cutler, S.J.; **McCurdy, C.R.** Sigma Receptor Blockade Potentiates the Analgesic Effects of Cannabinoids. (**Submission, 2016**).
2. Journigan, V.B.; Mesangeau, C.; Eans, S.O.; McLaughlin, J.P.; Mollereau, C.; Cutler, S.J.; **McCurdy, C.R.** The Discovery of Novel Mixed Opioid Agonists with Bifunctional Activity at Neuropeptide FF<sub>1</sub> and FF<sub>2</sub> Receptors. *Proceedings of the National Academy of Science USA* (**Submission, 2016**).

3. Hiranita, T.; Lopez, J.P.; Brellenthin, A.G.; Mesangeau, C.; Alsharif, W.; Kopajtic, T.A.; Sharma, A.; Jamalapuram, S.; Tsai, S.-Y.; Su, T.-P.; Tanda, G.; Avery, B.A.; Katz, J.L.; **McCurdy, C.R.** Preclinical efficacy of CM699 as a medication for stimulant abuse. *Proceedings of the National Academy of Science USA* (**Submission, 2016**).
4. Abdelazeem, A.H.; Mesangeau, C.; Seminario, M.; Jamalapuram, S.; El-Sayed Abbas, S.; Matsumoto, R.R.; Avery, B.A.; Poupaert, J.H.; **McCurdy, C.R.** Design and synthesis of metabolically stable benzothiazolone derivatives of CM156 with high affinity and selectivity for sigma ( $\sigma$ ) receptors. *Journal of Medicinal Chemistry* (**Submission, 2016**).
5. Shen, B.; Behera, D.; James, M.L.; Borgohain, P.; Reyes, S.T.; Cipriano, P.W.; Andrews, L.; Klukinov, M.; Lutz, A.B.; Mavlyutov, T.; Rosenberg, J.; Ruoho, A.E.; **McCurdy, C.R.**; Gambhir, S.S.; Yeomans, D.C.; Biswal, S.; Chin, F.T. Visualizing Nerve Injury in a Neuropathic Pain Model with [ $^{18}\text{F}$ ]FTC-146 PET/MRI. *Nature Biotechnology*, (**SUBMITTED**).
6. Shen, B.; Park, J.H.; Hjernevik, T.; Cipriano, P.W.; Yoon, D.; Gulaka, P.K.; Holly, D.; Behera, D.; Mitra, E.S.; Gambhir, S.S.; Avery, B.A.; **McCurdy, C.R.**; Biswal, S.; Chin, F.T. Initial Experience with Clinical-grade [ $^{18}\text{F}$ ]FTC-146: Radiosynthesis and First-in-human PET/MRI Evaluation. *American Journal of Nuclear Medicine and Molecular Imaging*, (**SUBMITTED**).
7. Avery, B.A.; Vuppala, P.K.; Jamalapuram, S.; Sharma, A.; Mesangeau, C.; Chin, F.T.; **McCurdy, C.R.** Quantification of Highly Selective Sigma-1 Receptor Antagonist CM304 using Liquid Chromatography Tandem Mass Spectrometry and its application to a Pre-clinical Pharmacokinetic Study. *Drug Testing and Analysis*, (**SUBMITTED**).
8. Lydecker, A.G.; Sharma, A.; **McCurdy, C.R.**; Avery, B.A.; Babu, K.M.; Boyer, E.W. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. *Journal of Medical Toxicology*, **2016**, XXX, XXX-XXX. (**IN PRESS**). Web Published October 17, 2016. DOI: 10.1007/s13181-016-0588-y PMID: 27752985 PMCID: pending.
9. Katz, J.L.; Hiranita, T.; Kopajtic, T.A.; Rice, K.C.; Mesangeau, C.; Narayanan, S.; Abdelazeem, A.H.; **McCurdy, C.R.** Blockade of Cocaine or Sigma Receptor Agonist Self-Administration by Selective Sigma Receptor Subtype-Selective Antagonists. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 358, 109-124. Web Published April 21, 2016. DOI: 10.1124/jpet.116.232728 PMID: 27189970 PMCID: pending
10. Nicholson, H.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Sigma-2 receptors play a role in cellular metabolism: Stimulation of glycolytic hallmarks by CM764 in human SK-N-SH neuroblastoma. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 356, 434-445. Web Published November 16, 2015. DOI: 10.1124/jpet.115.228387 PMID:26874517 PMCID: pending
11. Chu, U.B.; Mavlyutov, T.A.; Chu, M-L; Yang, H.; Schulman, A.; Mesangeau, C.; **McCurdy, C.R.**; Guo, L-W.; Ruoho, A.E. The Sigma-2 Receptor and PGRMC1 are Different Binding Sites Derived from Independent Genes. *EBioMedicine*, **2015**, 2, 1806-



1813. Web Published October 21, 2015. DOI: 10.1016/j.ebiom.2015.10.017 PMID: 26870805 PMCID: PMC4740303
12. Shen, B.; James, M.L.; Andrews, L.; Lau, C.; Chen, S.; Palner, M.; Miao, Z.; Arksey, N.C.; Shuhendler, A.; Scatliffe, S.; Kaneshige, K.; Parsons, S.M.; **McCurdy, C.R.**; Salehi, A.; Gambhir, S.S.; Chin, F.T. Further Validation to support clinical translation of [<sup>18</sup>F]FTC-146 for imaging sigma-1 receptors. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, *5*, 49. Web Published September 17, 2015. DOI: 10.1186/s13550-015-0122-2 PMID: 26384292 PMCID: PMC4573970
13. Kumarihamy, M.; Leon, F.; Pettaway, S.; Wilson, L.; Lambert, J.A.; Wang, M.; Hill, C.; **McCurdy, C.R.**; ElSohly, M.A.; Cutler, S.J.; Muhammad, I. In vitro Opioid Receptor Displacement Affinity and in vivo Behavioral Studies by Tetrad Assay of *Nelumbo nucifera* Flower. *Journal of Ethnopharmacology*, **2015**, *174*, 57-65. Web Published August 7, 2015. DOI: 10.1016/j.jep.2015.08.006 PMID: 26260436 PMCID: PMC4636954
14. Gbaguidi, F.A.; Kassehin, U.C.; Prevost, J.R.C.; Frederick, R.; **McCurdy, C.R.**; Poupaert, J.H. Insight into the Diels-Alder reaction: A green chemistry revisitation of the synthesis of a cantharidine-like trypanocidal pilot-molecule. *Journal of Chemical and Pharmaceutical Research*, **2015**, *7*, 1109-1113. Open Access Web Published: July 2015. ISSN: 0975-7384 CODEN(USA): JCPRC5
15. Kassehin, U.C.; Gbaguidi, F.A.; **McCurdy, C.R.**; Poupaert, J.H. Trypanocidal activity of a thioacyl-thiosemicarbazide derivative associating both immunostimulating thalidomide and anti-parasitic thiosemicarbazide pharmacophores. *Journal of Chemical and Pharmaceutical Research*, **2015**, *7*, 48-55. Open Access Web Published: July 2015. ISSN: 0975-7384 CODEN(USA): JCPRC5
16. Nicholson, H.; Comeau, A.; Mesangeau, C.; **McCurdy, C.R.**; Bowen, W.D. Characterization of CM572, a selective irreversible partial agonist of the sigma-2 receptor with Antitumor Activity. *Journal of Pharmacology and Experimental Therapeutics*, **2015**, *354*, 203-212. Web Published June 1, 2015. DOI: 10.1124/jpet.115.224105 PMID: 26034081 PMCID: PMC4518069
17. Abdelazeem, A.H.; Khan, S.I.; White, S.W.; Sufka, K.J.; **McCurdy, C.R.** Design, Synthesis and Biological Evaluation of Bivalent Benzoxazolone and Benzothiazolone Ligands, as Potential Anti-inflammatory/Analgesic Agents. *Bioorganic & Medicinal Chemistry*, **2015**, *23*, 3248-3259. Web Published April 25, 2015. DOI: 10.1016/j.bmc.2015.04.057 PMID: 25975638 PMCID: PMC4467529
18. Kassehin, U.C.; Gbaguidi, F.A.; Kapanda, C.N.; **McCurdy, C.R.**; Poupaert, J.H. Insight into the Willgerodt-Kindler reaction of  $\omega$ -haloacetophenone derivatives – Mechanistic Implication. *Organic Chemistry International*, **2014**, *2014*, 5 pages. Web Published December 10, 2014. DOI: 10.1155/2014/486540
19. Kassehin, U.C.; Gbaguidi, F.A.; Carato, P.; **McCurdy, C.R.**; Poupaert, J.H. Synthesis and Antiepileptic Activity Assessment of 5-Benzoyloxindole, a Novel Phenytoinergic

Template. *Organic Chemistry Current Research*, **2014**, *4*, 4 pages, Open Access Web Published: November 8, 2014. DOI: 10.4172/2161-0401.1000133

20. Kassehin, U.C.; Gbaguidi, F.A.; **McCurdy, C.R.**; Poupaert, J.H. Synthesis of antitrypanosomal thiosemicarbazones using anthranilic acid as an innovative *Green* nucleophilic catalyst. *Journal of Chemical and Pharmaceutical Research*, **2014**, *6*, 10, 607-612. Open Access Web Published: October, 2014. ISSN: 0975-7384 CODEN(USA): JCPRC5
21. Journigan, V.B.; Mesangeau, C.; Vyas, N.; Eans, S.O.; Cutler, S.J.; McLaughlin, J.P.; Mollereau, C.; **McCurdy, C.R.** Nonpeptide Small Molecule Agonist and Antagonist Original Leads for Neuropeptide FF1 and FF2 Receptors. *Journal of Medicinal Chemistry*, **2014**, *57*, 8903-8927. Web Published September 28, 2014. DOI: 10.1021/jm500989n PMID: 25268943 PMCID: PMC4234442
22. Kassehin, U.C.; Gbaguidi, F.A.; Kapanda, C.N.; **McCurdy, C.R.**; Poupaert, J.H. Solvent effect and catalysis in the synthesis of thiosemicarbazone derivatives from ketones and 4'-phenylthiosemicarbazide. *African Journal of Pure and Applied Chemistry*, **2014**, *8*, 110-115. DOI: 10.5891/AJPAC2014.0575
23. Abdelazeem, A.H.; Abdelatef, S.A.; El-Saadi, M.T.; Omar, H.A.; Khan, S.I.; **McCurdy, C.R.**; El-Moghazy, S.M. Novel Pyrazolopyrimidine Derivatives Targeting COXs and iNOS enzymes; Design, Synthesis and Biological Evaluation as Potential Anti-inflammatory Agents. *European Journal of Pharmaceutical Sciences*, **2014**, *62*, 197-211. Web Published June 4, 2014. DOI: 10.1016/j.ejps.2014.05.025 PMID: 24907682 PMCID: Pending
24. Husni, A.S.; **McCurdy, C.R.**; Radwan, M.M.; Ahmed, S.A.; Slade, D.; Ross, S.A.; ElSohly, M.A.; Cutler, S.J. Evaluation of Phytocannabinoids from High Potency *Cannabis sativa* using *In Vitro* Bioassays to Determine Structure-Activity Relationships for Cannabinoid Receptor 1 and Cannabinoid Receptor 2. *Medicinal Chemistry Research*, **2014**, *23*, 4295-4300. Web Published April 26, 2014. DOI: 10.1007/s00044-014-0972-6 PMID: 25419092 PMCID: PMC4235762
25. Robson, M.J.; Turner, R.C.; Naser, Z.J.; **McCurdy, C.R.**; O'Callaghan, J.P.; Huber, J.D.; Matsumoto, R.R. SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. *Experimental Neurology*, **2014**, *254*, 180-189. Web Published February 6, 2014. DOI: 10.1016/j.expneurol.2014.01.020 PMID: 24508558 PMCID: PMC4241368
26. Kaushal, N.; Robson, M.J.; Rosen, A. **McCurdy, C.R.**; Matsumoto, R.R. Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro. *European Journal of Pharmacology*, **2014**, *724*, 193-203. Web Published December 28, 2013. DOI: 10.1016/j.ejphar.2013.12.039 PMID: 24380829 PMCID: PMC3993961

27. James, M.L.; Shen, B.; Nielsen, C.H.; Behera, D.; Buckmaster, C.L.; Mesangeau, C.; Zavaleta, C.; Vuppala, P.K.; Jamalapuram, S.; Avery, B.A.; Lyons, D.M.; **McCurdy, C.R.**; Biswal, S.; Gambhir, S.S.; Chin, F.T. Evaluation of Sigma-1 Receptor Radioligand [<sup>18</sup>F]FTC-146 in Rats and Squirrel Monkeys using Positron Emission Tomography. *Journal of Nuclear Medicine*, **2014**, *55*, 147-153. Web Published December 12, 2013. DOI: 10.2967/jnumed.113.120261 PMID: 24337599 PMCID: PMC4170105
28. Tarawneh, A.H.; Leon, F.; Ibrahim, M.A.; Pettaway, S.; **McCurdy, C.R.**; Cutler, S.J. Flavones from *Miconia prasina*. *Phytochemistry Letters*, **2014**, *7*, 130-132. Web Published December 4, 2013. DOI: 10.1016/j.phytol.2013.11.001 PMID: 24976876 PMCID: PMC4070512
29. Kassehin, U.C.; Gbaguidi, F.A.; Kapanda, C.N.; **McCurdy, C.**; Bigot, A.K.; Poupaert, J.H. Electronic and steric effects in the control of the Anilinium chloride catalyzed condensation reaction between Aldones and 4-Phenylthiosemicarbazide. *African Journal of Pure and Applied Chemistry*, **2013**, *7*, 325-392. DOI: 10.5897/AJPAC2013.0514
30. Gregg, R.A.; Tallarida, C.S.; Reitz, A.; **McCurdy, C.**; Rawls, S.M. Mephedrone (4-methylmethcathinone), a principal constituent of psychoactive bath salts, produces behavioral sensitization in rats. *Drug and Alcohol Dependence*, **2013**, *133*, 746-750. Web Published July 23, 2013. DOI: 10.1016/j.drugalcdep.2013.06.014 PMID: 23890492 PMCID: PMC3989200
31. Vuppala, P.K.; Jamalapuram, S.; Furr, E.B.; **McCurdy, C.R.**; Avery, B.A. Development and validation of a UPLC-MS/MS method for the determination of 7-hydroxymitragynine, a  $\mu$ -opioid agonist, in rat plasma and its application to a pharmacokinetic study. *Biomedical Chromatography*, **2013**, *12*, 1726-1732. Web Published July 24, 2013. DOI: 10.1002/bmc.2986 PMID: 23893615 PMCID: PMC4029328
32. Bhat, R.; Fishback, J.A.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Structure Activity Relationship of benzo[d]thiazol-2(3H)one Based Sigma Receptor Ligands. *Bioorganic Medicinal Chemistry Letters*, **2013**, *23*, 5011-5013. Web Published June 29, 2013. DOI: 10.1016/j.bmcl.2013.06.032 PMID: 23867168 PMCID: PMC3762478
33. Robson, M.J.; Seminerio, M.J.; **McCurdy, C.R.**; Coop, A.; Matsumoto, R.R. Sigma receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. *Pharmacological Reports*, **2013**, *65*, 343-349. DOI: 10.1016/S1734-1140(13)71009-0 PMID: 23744418
34. Jamalapuram, S.; Vuppala, P.K.; Abdelazeem, A.H.; **McCurdy, C.R.**; Avery, B.A. Ultra performance liquid chromatography tandem mass spectrometry method for the determination of AZ66, a sigma receptor ligand, in rat plasma and its application to in vivo pharmacokinetic study. *Biomedical Chromatography*, **2013**, *27*, 1034-1040. Web Published 4-5-2013. DOI: 10.1002/bmc.2901 PMID: 23558564 PMCID: PMC4122523
35. Robson, M.J.; Turner, R.C.; Naser, Z.J.; **McCurdy, C.R.**; Huber, J.D.; Matsumoto, R.R. SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation

- and cytokine upregulation. *Experimental Neurology*, **2013**, *247C*, 134-142. Web Published 4-27-2013. DOI: S0014-4886(13)00137-4. 10.1016/j.expneurol.2013.04.009 PMID: 23631864 PMCID: PMC3742718
36. Giacometti, R.D.; Duchek, J.; Werner, L.; Husni, A.S.; **McCurdy, C.R.**; Cutler, S.J.; Cox, D.P.; Hudlicky, T. Heteroatom Analogues of Hydrocodone: Synthesis and Biological Activity. *Journal of Organic Chemistry*, **2013**, *78*, 2914-2925. Web Published 2-11-2013. DOI: 10.1021/jo3026753 PMID: 23397939 PMCID: PMC3618612
37. Poupaert, J.H.; Gbaguidi, F.A.; Kapanda, C.N.; Aichaoui, H.; **McCurdy, C.R.** Is Cocaine a Social Drug? Exploration of the Stereo-structure of Cocaine's Pharmacophore. *Medicinal Chemistry Research*, **2013**, *22*, 247-252. Web Published 3-25-2012. DOI: 10.1007/s00044-012-0005-2
38. Kaushal, N.; Seminerio, M.J.; Robson, M.J.; **McCurdy, C.R.**; Matsumoto, R.R. Pharmacological evaluation of SN79, a sigma ( $\sigma$ ) receptor putative antagonist, against methamphetamine-induced neurotoxicity in vivo. *European Neuropsychopharmacology*, **2013**, *23*, 960-971. Web Published 8-24-2012. DOI: 10.1016/j.euroneuro.2012.08.005 PMID: 22921523. PMCID: PMC3748261
39. Harden, M.T.; Smith, S.E.; Niehoff, J.A.; **McCurdy, C.R.**; Taylor, G.T. Antidepressive effects of the  $\kappa$ -opioid receptor agonist salvinorin A in a rat model of anhedonia. *Behavioural Pharmacology*, **2012**, *23*, 710-715. Web Published 8-23-2012. DOI: 10/1097/FBP.0b013e3283586189 PMID: 22926298
40. Seminerio, M.J.; Hansen, R.; Kaushal, N.; Zhang, H.T.; **McCurdy, C.R.**; Matsumoto, R.R. The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. *International Journal of Neuropsychopharmacology*, **2012**, *16*, 1033-1044. Web Published 8-29-2012. DOI: 10.1017/S1461145712000831 PMID: 22932447
41. Seminerio, M.J.; Robson, M.J.; **McCurdy, C.R.**; Matsumoto, R.R. Sigma receptor antagonists attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1 $\beta$  mRNA expression in the hypothalamus. *European Journal of Pharmacology*, **2012**, *691(1-3)*, 103-109. Web Published 7-20-2012. DOI: 10.1016/j.ejphar.2012.07.029 PMID: 22820108 PMCID: PMC3726051
42. Fishback, J.A.; Rosen, A.; Bhat, R.; **McCurdy, C.R.**; Matsumoto, R.R. A 96-well method for the analysis of sigma receptor radioligand binding. *Journal of Pharmaceutical and Biomedical Analysis*, **2012**, *71*, 157-161. Web Published 8-9-2012. DOI: 10.1016/j.jpba.2012.07.023 PMID: 22910107 PMCID: PMC3726061
43. James, M.L.; Shen, B.; Zavaleta, C.L.; Nielsen, C.H.; Mesangeau, C.; Vupalla, P.K.; Chan C.; Avery, B.A.; Fishback, J.A.; Matsumoto, R.R.; Gambhir, S.S.; **McCurdy, C.R.**; Chin, F.T. A New Positron Emission Tomography (PET) Radioligand for Imaging Sigma-1 Receptors in Living Subjects. *Journal of Medicinal Chemistry*, **2012**, *55*, 8272-8282. Web Published 8-1-2012. DOI: 10.1021/jm300371c PMID: 22853801

44. Nieto, M.J.; Pierini, A.B.; Singh, N.; **McCurdy, C.R.**; Manzo, R.H.; Mazzieri, M.R. SAR Analysis of New Dual Targeting Fluoroquinolones. Implications of the Benzenesulfonyl Group. *Medicinal Chemistry*, **2012**, *8*, 349-360. Web Published 4-24-2012. PMID: 22530906
45. Xu, Y.T.; Robson, M.J.; Szeszel-Fedorowicz, W.; Patel, D.; Rooney, R.; **McCurdy, C.R.**; Matsumoto, R.R. CM156, a Sigma Receptor Ligand, Reverses Cocaine-Induced Place Conditioning and Transcriptional Responses in the Brain. *Pharmacology, Biochemistry and Behavior*, **2012**, *101*, 174-180. Web Published 12-30-2011. DOI: 10.1016/j.pbb.2011.12.016 PMID: 22234290 PMCID: PMC3726055
46. Seminerio, M.J.; Robson, M.J.; Abdelazeem, A.H.; Mesangeau, C.; Avery, B.A.; **McCurdy, C.R.**; Matsumoto, R.R. Synthesis and Pharmacological Characterization of a Novel Sigma Receptor Ligand with Improved Metabolic Stability and Antagonistic Effects Against Methamphetamine. *AAPS Journal*, **2012**, *14*, 43-51. Web Published 12-20-2011. DOI: 10.1208/s12248-011-9311-8 PMID: 22183188
47. Jamalapuram, S.; Vuppala, P.K.; Mesangeau, C.; **McCurdy, C.R.**; Avery, B.A. Determination of CM156, a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. *Journal of Chromatography B*, **2012**, *891-892*, 1-6. Web Published 12-20-2011. DOI: 10.1016/j.jchromb.2011.12.013 PMID: 22406103
48. Mesangeau, C.; Amata, E.; Alsharif, W.; Seminerio, M.J.; Robson, M.J.; Matsumoto, R.R.; **McCurdy, C.R.** Synthesis and pharmacological evaluation of indole-based sigma receptor ligands. *European Journal of Medicinal Chemistry*, **2011**, *46*, 5154-5161. Web Published 8-29-2011. DOI: 10.1016/j.ejmech.2011.08.031 PMID: 21899931 PMCID: PMC3272488
49. Vuppala, P.K.; Boddu, S.P.; Furr, E.B.; **McCurdy, C.R.**; Avery, B.A. Development and Validation of a Simple, Sensitive, High-Throughput Method for the Quantification of Mitragynine in Rat Plasma using Ultra Performance Liquid Chromatography-Mass Spectrometry and its Application to an Intravenous Pharmacokinetic Study. *Chromatographia*, **2011**, *74*, 703-710. Web Published 7-31-2011. DOI: 10.1007/s10337-011-2128-x
50. Kaushal, N.; Seminerio, M.J.; Shaikh, J.; Medina, M.A.; Mesangeau, C.; Wilson, L.L.; **McCurdy, C.R.**; Matsumoto, R.R. CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice. *Neuropharmacology*, **2011**, *61*, 992-1000. Web Published 7-7-2011. DOI: 10.1016/j.neuropharm.2011.06.028. PMID: 21762711 PMCID: PMC3615888
51. Kaushal, N.; Robson, M.J.; Vinnakota, H.; Narayanan, S.; Avery, B.A.; **McCurdy, C.R.**, Matsumoto, R.R. Synthesis and Pharmacological Evaluation of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a Cocaine Antagonist, in Rodents. *The AAPS Journal*, **2011**, *13*, 336-346. Web Published 4-15-2011. DOI: 10.1208/s12248-011-9274-9. PMID: 21494909

52. Yekkirala, A.S.; Lunzer, M.M.; **McCurdy, C.R.**, Powers, M.D.; Kalyuzhny, A.E.; Roerig, S.C.; Portoghese, P.S. *N*-Naphthoyl- $\beta$ -naltrexamine (NNTA), a highly selective and potent activator of heteromeric  $\mu$ /kappa opioid receptors. *Proceedings of the National Academy of Science USA*, **2011**, *108*, 5098-5103. Web Published 3-8-2011. DOI: 10.1073/pnas.1016277108
53. Chajkowski, S.M.; Mallela, J.; Watson, D.E.; Wang, J.; **McCurdy, C.R.**; Rimoldi, J.M.; Shariat-Madar, Z. Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase. *Biochemical and Biophysical Research Communications*, **2011**, *405*, 338-343. Web Published 12-16-2010. DOI: 10.1016/j.bbrc.2010.12.036
54. Guenadil, F.; Aichaoui, H.; Kapanda, C.N.; Lambert, D.M.; **McCurdy, C.R.**; Poupaert, J.H. Design and synthesis of 3-acyl-2(3*H*)-benzoxazolone and 3-acyl-2(3*H*)-benzothiazolone derivatives. *Monatshefte fur Chemie (Chemical Monthly)*. **2011**, *142*, 67-80. Web Published 12-2-2010. DOI: 10.1007/s00706-010-0419-9
55. Fishback, J.A.; Mesangeau, C.; Poupaert, J.H.; **McCurdy, C.R.**; Matsumoto, R.R. Synthesis and characterization of [<sup>3</sup>H]SN56, a novel radioligand for the sigma-1 receptor. *European Journal of Pharmacology*, **2011**, *653*, 1-7. Web Published 12-6-2010. DOI: 10.1016/j.ejphar.2010.10.099 PMID: 21130085 PMCID: PMC3726058
56. Garces-Ramirez, L.; Green, J.L.; Hiranita, T.; Kopajtic, T.A.; Mereu, M.; Thomas, A.; Mesangeau, C.; Narayanan, S.; **McCurdy, C.R.**; Katz, J.L.; Tanda, G. Sigma receptor agonists: Receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis in rats. *Biological Psychiatry*, **2011**, *69*, 208-217. Web Published 10-14-2010. DOI: 10.1016/j.biopsych.2010.07.026
57. Liu, H.; **McCurdy, C.R.**; Doerksen, R.J. Computational Study on the Conformations of Mitragynine and Mitragynaline. *Journal of Molecular Structure: THEOCHEM*. **2010**, *945*, 57-63. Web Published 1-18-2010. DOI: 10.1016/j.theochem.2010.01.011
58. Xu, Y.T.; Kaushal, N.; Shaikh, J.; Wilson, L.L.; Mesangeau, C.; **McCurdy, C.R.**; Matsumoto, R.R. A novel substituted piperazine, 3-(4-(4-cyclohexylpiperazine-1-yl)butyl)benzo[d]thiazole-2(3*H*)-thione (CM156), attenuates the stimulant and toxic effects of psychostimulants in mice: Effects on cocaine. *Journal of Pharmacology and Experimental Therapeutics*. **2010**, *333*, 491-500. Web Published 1-25-2010. DOI: 10.1124/jpet.109.161398
59. Leon, F.; Habib, E.; Adkins, J.E.; Furr, E.B.; **McCurdy, C.R.**; Cutler, S.J. Phytochemical characterization of the leaves of *Mitragyna speciosa* grown in USA. *Natural Product Communications*. **2009**, *4*, 907-910.
60. de Moraes, N.V.; Moretti, R.A.C.; Furr, E.B.; **McCurdy, C.R.**; Lanchote, V.L. Determination of mitragynine in rat plasma by LC-MS-MS: Application to pharmacokinetics. *Journal of Chromatography B*. **2009**, *877*, 2593-2597. Web Published 6-21-2009. DOI: 10.1016/j.jchromb.2009.06.023

61. Carvalho, P.; Furr, E.B. III; **McCurdy, C.R.** (E)-methyl 2-((2S,3S,12bR)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo [2,3-a]quinolizin-2-yl)-3-methoxyacrylate. *Acta Cryst.* **2009**, *E65*, o1441-o1442. Web Published 5-29-2009. DOI: 10.1107/S1600536809017309
62. Dayan, F.; Singh, N.; **McCurdy, C.R.**; Godfrey, C.; Larsen, L.; Weavers, R.; Van Klink, J.; Perry, N.  $\beta$ -Triketone Inhibitors of Plant *p*-Hydroxyphenylpyruvate Dioxygenase: Modeling and Comparative Molecular Field Analysis of their Interactions. *J. Agric. Food Chem.*, **2009**, *57*, 5194-5200. Web Published 5-12-2009. DOI: 10.1021/jf9005593
63. Aichaoui, H.; Guenadil, F.; **McCurdy, C.R.**; Coco, N.; Lambert, D.M.; Poupaert, J.H. Synthesis and pharmacological evaluation of antioxidant chalcone derivatives of 2(3*H*)-benzoxazolones. *Med. Chem. Res.*, **2009**, *18*, 665-668. Web Published 12-4-2008. DOI: 10.1007/s00044-008-9143-y
64. Guenadil, F.; Aichaoui, H.; Lambert, D.M.; **McCurdy, C.R.**, Poupaert, J.H. Highly selective catalytic Friedel-Crafts acylation of activated aromatic compounds using I<sub>2</sub>-DMF complex as catalyst. *Lett. Org. Chem.*, **2008**, *5*, 665-668. DOI: 10.2174/157017808786857624
65. Singh, N.; Nolan, T.L.; **McCurdy, C.R.** Chemical Function Based Pharmacophore Development for Novel, Selective Kappa Opioid Receptor Agonists. *J. Mol. Graph. Model.*, **2008**, *27*, 131-139. Web Published 3-29-2008. DOI: 10.1016/j.jmgm.2008.03.007
66. Boyer, E.W.; Babu, K.M.; Adkins, J.E.; **McCurdy, C.R.**, Halpern, J.H. Self-Treatment of Chronic Pain and Opioid Withdrawal with Kratom. *Addiction*, **2008**, *103*, 1048-1050. DOI: 10.1111/j.1360-0443.2008.02209.x
67. Kane, B.; **McCurdy, C.R.**, Ferguson, D.M. Towards a Structure-Based Model of Salvinorin A Recognition of the Kappa Opioid Receptor. *J. Med. Chem.* **2008**, *51*, 1824-1830. Web Published 2-23-2008. DOI: 10.1021/jm701040v
68. Mesangeau, C.; Narayanan, S.; Shaikh, J.; Kaushal, N.; Viard, E.; Xu, Y.; Matsumoto, R.R.; Poupaert, J.H.; **McCurdy, C.R.** Conversion of a highly selective sigma-1 receptor ligand to sigma-2 receptor preferring ligands with anti-cocaine activity. *J. Med. Chem.*, **2008**, *51*, 1482-1486. Web Published 2-16-2008. DOI: 10.1021/jm701357m
69. Babu, K.M.; **McCurdy, C.R.**; Boyer, E.W. Opioid Receptors and Legal Highs: *Salvia divinorum* and kratom. *Clin. Toxicol.* **2008**, *46*, 146-152. Web Published 1-10-2008. DOI: 10.1080/15563650701241795
70. Willmore-Fordham C.B.; Krall, D.M., **McCurdy, C.R.**; Kinder, D.H. The hallucinogen derived from *Salvia divinorum*, salvinorin A, has kappa opioid agonist discriminative stimulus effects in rats. *Neuropharmacol.* **2007**, *53*, 481-486. Web Published 6-27-2007. DOI: 10.1016/j.neuropharm.2007.06.008

71. Prabhu-Haris, S.; Zhang, Y.; Le Bourdonnec, B.; **McCurdy, C.R.**; Portoghese, P.S. *o*-Naphthalenedicarboxaldehyde Derivative of 7'-Aminonaltrindole as a Selective  $\delta$ -Opioid Receptor Affinity Label. *J. Med. Chem.* **2007**, *50*, 3392-3396. Web Published 6-8-2007. DOI: 10.1021/jm061194h
72. Singh, N.; Avery, M.A.; **McCurdy, C.R.** Toward *Mycobacterium tuberculosis* DXR Inhibitor Design: Homology Modeling, Docking Studies, and Molecular Dynamics Simulations. *J. Comput. Aided Mol. Des.* **2007**, *21*, 511-522. Web Published 9-14-2007. DOI: 10.1007/s10822-007-9132-0
73. Singh, N.; Cheve, G.; Avery, M.A.; **McCurdy, C.R.** Targeting the Methyl Erythritol Phosphate (MEP) Pathway for Novel Antimalarial, Antibacterial and Herbicidal Drug Discovery: Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) Enzyme. *Curr. Pharm. Des.* **2007**, *13*, 1161-1177.
74. Philip, A.E.; Poupaert, J.H.; Cheve, G.; Muccioli, G.; Lambert, D.; **McCurdy, C.R.** Structure-Activity Relationships of Phenytoinergic Antiepileptic Drugs Related to Ameltolide. *Med. Chem. Res.* **2007**, *15*, 130-135. Web Published 7-26-2007. DOI: 10.1007/s00044-007-9016-9
75. Dayan, F.E.; Duke, S.O.; Sauldubois, A.; Singh, N.; **McCurdy, C.**; Cantrell, C. *p*-Hydroxyphenylpyruvate Dioxygenase is a Target Site for  $\beta$ -Triketone Phytochemicals. *Phytochemistry* **2007**, *68*, 2004-2014. Web Published 3-17-2007. DOI: 10.1016/j.phytochem.2007.01.026
76. Singh, N.; Cheve, G.; Ferguson, D.M.; **McCurdy, C.R.** A Combined Ligand-Based and Target-Based Drug Design Approach for G-Protein Coupled Receptors: Application to Salvinorin A, A Selective Kappa Opioid Receptor Agonist. *J. Comput. Aided Mol. Des.* **2006**, *20*, 471-493. Web Published 9-29-2006. DOI: 10.1007/s10822-006-9067-x
77. Kane, B.E.; **McCurdy, C.R.**; Nieto, M.J.; Ferguson, D.M. A Unique Binding Epitope for Salvinorin A, a Non-Nitrogenous Kappa Opioid Receptor Agonist. *FEBS J.* **2006**, *273*, 1966-1974. Web Published 4-5-2006. DOI: 10.1111/j.1742-4658.2006.05212.x
78. Singh, N.; Cheve, G.; Avery, M.A.; **McCurdy, C.R.** Comparative Protein Modeling of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase Enzyme from *Plasmodium falciparum*: A Potential Target for Antimalarial Drug Discovery. *J. Chem. Inf. Model.* **2006**, *46*, 1360-1370. Web Published 4-4-2006. DOI: 10.1021/ci050523w
79. **McCurdy, C.R.**; Sufka, K.J.; Smith, G.H.; Warnick, J.E.; Nieto, M.J. Analgesic Profile of Salvinorin A, a Structurally Unique Kappa Opioid Receptor Agonist. *Pharmacol. Biochem. Behav.*, **2006**, *83*, 109-113. Web Published 1-23-2006. DOI: 10.1016/j.pbb.2005.12.011
80. Yous, S.; Wallez, V.; Belloir, M.; Caignard, D.H.; **McCurdy, C.R.**; Poupaert, J.H. Novel 2(3*H*)-Benzothiazolones as Highly Potent and Selective Sigma-1 Receptor Ligands. *Med. Chem. Res.*, **2005**, *14*, 158-168. DOI: 10.1007/s00044-005-0131-1



81. Geldenhuys, W.J.; Lockman, P.R.; Philip, A.E.; Miller, B.L.; **McCurdy, C.R.**; Allen, D.D. Inhibition of choline uptake by *N*-cyclohexylcholine, a high affinity ligand for the choline transporter at the Blood-Brain Barrier. *J. Drug Target.*, **2005**, *13*, 259-266. DOI: 10.1080/10611860500139222
82. Poupaert, J.H.; Carato, P.; **McCurdy, C.R.** A Simple and Effective Method for the Thionation of Amides to Thioamides using Al<sub>2</sub>O<sub>3</sub>-supported P<sub>4</sub>S<sub>10</sub>. *Lett. Org. Chem.*, **2005**, *2*, 330-333. DOI: 10.2174/1570178054038957
83. Warnick, J.E.; **McCurdy, C.R.**; Sufka, K.J. Opiate Modulation of Social Attachment. *Behav. Brain Res.*, **2005**, *160*, 277-285. Web Published 1-16-2005. DOI: 10.1016/j.bbr.2004.12.009
84. Nieto, M.; Philip, A.E.; Poupaert, J.H.; **McCurdy, C.R.** Solution Phase Parallel Synthesis of Spirohydantoin. *J. Combi. Chem.*, **2005**, *7*, 258-263. Web Published 12-24-2004. DOI: 10.1021/cc049870t
85. Zhang, Y.; **McCurdy, C.R.**; Metzger, T.G.; Portoghese, P.S. Specific cross-linking of LYS233 and CYS235 in the mu opioid receptor by a reporter affinity label. *Biochemistry*, **2005**, *44*, 2271-2275. Web Published 1-25-2005. DOI: 10.1021/bi048049v
86. Poupaert, J.H.; Duarte, S.; Depreux, P.; **McCurdy, C.R.**; Lambert, D.L. Willgerodt-Kindler's Microwave-enhanced Synthesis of Thioamide Derivatives. *Phosphorus, Sulfur, and Silicon and the related elements*. **2004**, *179*, 1959-1973. DOI: 10.1080/10426500490466977
87. Poupaert, J.H.; Depreux, P.; **McCurdy, C.R.** Unsymmetrical diarylketones from electron-rich heterocyclic arenes. *Monatshfte für Chemie (Chemical Monthly)*. **2003**, *134*, 823-830. Web Published 3-6-2003. DOI: 10.1007/s00706-002-0573-9
88. **McCurdy, C.R.**; Le Bourdonnec, B.; Metzger, T.G.; El Kouhen, R.; Zhang, Y.; Law, P.Y.; Portoghese, P.S. Naphthalene dicarboxaldehyde as an electrophilic fluorogenic moiety for affinity labeling: Application to opioid receptor affinity labels with greatly improved fluorogenic properties. *J. Med. Chem.* **2002**, *45*, 2887-2890. Web Published 6-12-2002. DOI: 10.1021/jm015586u
89. **McCurdy, C.R.**; Jones, R.M.; Portoghese, P.S. Investigation of phenolic bioisosterism in opioids: Synthesis and biological evaluation of 3-methylsulfonamide analogues of naltrexone and oxymorphone. *Org. Lett.* **2000**, *2*, 819-821. DOI: 10.1021/ol005561+
90. **McCurdy, C.R.**; Venkateshwaran, T.G.; Beach, J.W.; Stewart, J.T. Capillary electrophoretic separation of lobeline analogues using derivatized cyclodextrins: Effects of pH, additive and organic modifier concentration. *Electrophoresis*, **1999**, *20*, 212-218. DOI: 10.1002/(SICI)1522-2683(19990101)20:1<212::AID-ELPS212>3.0.CO;2-I
91. Metting T.L.; Burgio D.E.; Terry A.V.; Beach J.W.; **McCurdy C.R.**; Allen D.D. Inhibition of choline uptake by isoarecolone and lobeline derivatives: Implications for

potential vector mediated brain drug delivery. *Neurosci. Lett.* **1998**, *258*, 25-28. DOI: 10.1016/S0304-3940(98)00871-4

92. Terry Jr., A.V.; Williamson, R.; Gattu, M.; Beach, J.W.; **McCurdy, C.R.**; Sparks, J.A.; Pauly, J.R. Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. *Neuropharmacol.* **1998**, *37*, 93-102. DOI: 10.1016/S0028-3908(97)00142-1
93. Beach, J.W.; **McCurdy, C.R.**; Gattu, M.; Boss, K.L.; Templeton, R.E.; Terry Jr., A.V. Synthesis and receptor binding of N-substituted-2-styryl-1,2,3,6-tetrahydropyridines as potential nicotinic agonists. *Med. Chem. Res.* **1997**, *7*, 271-281.

## PROFESSIONAL PUBLICATIONS

### MANUSCRIPTS:

1. **McCurdy, C.R.** Strategies to treat substance abuse and addiction. *Current Topics in Medicinal Chemistry*, **2011**, *11*, 1102. *Editorial*
2. **McCurdy, C.R.** Drug Design and Discovery: D3I Current Trends and Implications for Academia. *AAPS Newsmagazine*, **2009**, *12*, 16-23. **Featured Cover Story**, July Issue.
3. Martinez, M.N.; Bonate, P.; Chapman, R.L.; De Groot, A.; D'Souza, S.; Ghilazi, N.; Gray, V.; Gupta, V.K.; Huynh-Ba, K.; Iyer, S.; Jayatilaka, A.; Joshi, A.; Karnes, H.T.; Kahn, M.; Liu, P.; Lunte, C.; **McCurdy, C.R.**; Morris, M.E.; Norris, K.J.; Ramsey, P.; Sehgal, S.; Zahn, M. 2007 Highlights of Advances in Pharmaceutical Sciences: An American Association of Pharmaceutical Scientists (AAPS) Perspective. *AAPS Journal*, **2007**, *9*, Article 24. DOI: 10.1208/aapsj0902024
4. **McCurdy, C.R.** Pharmacy Education: From Prescott to Pharmacogenomics. *Journal of the American Pharmaceutical Association* **2002**, *42*, 688-691.

### PUBLISHED ABSTRACTS:

1. **McCurdy, C.R.**, Nieto, M.J.; Kane, B.E.; Ferguson, D.M. Non-nitrogenous kappa opioid receptor ligands based on salvinorin A, a unique and naturally occurring opiate lead. *Fundamental and Clinical Pharmacology*, **2004**, *18*, 597. DOI: 10.1111/j.1472-8206.2004.00288.x
2. **McCurdy, C.R.**; Sufka, K.J.; Warnick, J.E.; Nieto, M.J. Salvinorin A, a Kappa Opioid Receptor Agonist is a Fast Acting, Potent Analgesic. Abstract for presentation at the American Association of Pharmaceutical Scientists/National Institute of Drug Abuse Symposium Frontiers in Science, Drug Addiction – From Basic Research to Therapies. *The AAPS Journal*, **2004**, *6*. [http://www.aapsj.org/theme\\_issues/theme\\_issue7.asp](http://www.aapsj.org/theme_issues/theme_issue7.asp)
3. Metting T.L.; Burgio D.E.; Terry A.V.; Beach J.W.; **McCurdy C.R.**; Allen D.D. Evaluation of lobeline and arecoline derivative inhibition of blood-brain barrier (BBB) choline transport by the in situ brain perfusion technique. Abstract for presentation at the

American Association of Pharmaceutical Scientists annual meeting, San Francisco, California. *PharmSci.*, **1998**, (Suppl) 1(1): S395.

4. Smith, J.B.; **McCurdy, C.R.**; Beach, J.W.; Cutler, S.J. Behavioral and discriminative-stimulus effects of nicotinic agonists. Abstract for presentation at the Experimental Biology annual meeting. *FASEB Journal*, **1998**, 12, pA137.

#### INVITED BOOK REVIEWS:

1. **McCurdy, C.R.** Modern Alkaloids. Structure, Isolation, Synthesis and Biology edited by Ernesto Fattorusso and Orazio Taglialatela-Scafati. *J. Med. Chem.*, **2008**, 51, 4356.

#### BOOK CHAPTERS:

1. Leon, F.; Gogineni, V.; Avery, B.A.; **McCurdy, C.R.**; Cutler, S.J. Phytochemistry of *Mitragyna speciosa*. In: Kratom and Other Mitragynines: The Chemistry and Pharmacology of Opioids from a Non-Opium Source. Ed. Raffa, R.B. CRC Press, USA, **2014**. pp 77-94. ISBN: 978-1-4822-2518-1
2. **McCurdy, C.R.**; Prisinzano, T.E. Opioid Receptor Ligands. In: Burger's Medicinal Chemistry, Drug Discovery and Development. Volume 8. Eds. Abraham, D.J.; Rotella, D.P. 7<sup>th</sup> Ed. Wiley, **2010**. ISBN: 978-0-470-27815-4
3. Nolan, T.L.; Singh, N.; **McCurdy, C.R.** Ligand Macromolecule Interactions: Theoretical Principles of Molecular Recognition. In: Methods in Molecular Biology; 572 Ligand-Macromolecule Interactions in Drug Discovery. Ed. Roque, A.C.A. Humana Press, USA, **2010**. pp 13-29. ISBN: 978-1-60761-243-8
4. **McCurdy, C.R.** Development of Opioid Receptor Ligands. In: Analog-Based Drug Discovery. Eds. Fischer, J.; Ganellin, C.R. IUPAC. Wiley-VCH, **2005**. pp 259-276. ISBN: 3-527-31257-9
5. **McCurdy, C.R.**, Miller, R.L., and Beach, J.W. Lobeline: A Natural Product With High Affinity for Neuronal Nicotinic Receptors and a Vast Potential for use in Neurological Disorders. Biologically Active Natural Products: Pharmaceuticals. Eds. Cutler, S.J., and Cutler, H.G. CRC Press LLC, **2000**.

#### PATENTS ISSUED:

1. **McCurdy, Christopher R.**; Mesangeau, Christophe; Matsumoto, Rae R.; Poupaert, Jacques H.; Avery, Bonnie A.; Abdelazeem, Ahmed H. Highly Selective Sigma Receptor Ligands. United States Patent US 8,686,008 B2, April 1, 2014.
2. **McCurdy, Christopher R.**; Mesangeau, Christophe; Narayanan, Sanju; Matsumoto, Rae Reiko; Poupaert, Jacques Henri. Highly Selective Sigma Receptor Ligands. United States Patent US 8,809,381, August 19, 2014.

#### PATENTS PENDING:

3. **McCurdy, C.R.** Highly Selective Sigma Receptor Ligands. U.S. Provisional Patent Application No. 60/956,249, Filed 8/16/2007.
4. **McCurdy, C.R.** Synthesis and Evaluation of Dual-Activity Opioid-NPFF Ligands for Receptor Affinity, Antinociception and Tolerance Liabilities. U.S. Provisional Patent Application No. 62026378, Filed 7/18/2014.
5. **McCurdy, C.R.**; Mesangeau, C.; Narayanan, S.; Matsumoto, R.R.; Poupaert, J.H. Highly Selective Sigma Receptor Ligands. WO2009/026227 A2. Priority Date 08/16/2007. International Filing Date: 08/18/2008. International Application Number: PCT/US2008/073478.
6. **Boyer, E.W.** Method for Treating Withdrawal From Addictive Compounds. U.S. Provisional Patent Application No. 61116912. Filed 11/21/2008. Priority Application US 2008-116912P. Date: 11/21/2008.
7. **McCurdy, C.R.**; Mesangeau, C.; Narayanan, S.; Matsumoto, R.R.; Poupaert, J.H.; Avery, B.A.; Abdelazeem, A.H. Highly Selective Sigma Receptor Ligands. U.S. Application Number: 12/785,217. Filed 05/21/2010
8. Boyer, E.W.; **McCurdy, C.R.**; Adkins, J.E. Methods for treating withdrawal from addictive compounds using Kratom. U.S. Application Number 20100209542 A1. Date: 08/19/2010.

#### **INVESTIGATIONAL NEW DRUG (IND) APPLICATONS:**

1. On May 28, 2015 our collaborative team (filed under Sanjiv Sam Gambhir, M.D., Ph.D.) had an eIND (126459) approved on May 28, 2015 to proceed with study by the US FDA (submitted April 24, 2015). This eIND will utilize our original sigma-1 receptor antagonist (CM304/FTC146) as a PET/MR imaging diagnostic agent. This has been accomplished with funds in part from the National Institutes of Health (NIDA & NIGMS), the University of Mississippi and Stanford University. Clinical studies will involve 40 human volunteers and will be carried out at Stanford University School of Medicine. **The first patient was completed on February 9, 2016 and the trials are currently ongoing.**